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Abstract 
 
Amy Elizabeth Webb 
Linkage, Association, And Haplotype Analysis: A Spectrum Of Approaches To Elucidate 
The Genetic Influences Of Complex Human Disease 
Under the direction of Kirk Wilhelmsen 
 
The goal of human genetics is to identify genetic variants that influence a certain trait with 
the intent to provide a better understanding of the biology behind that trait.  As technologies 
and statistical methods towards this goal have developed, there has been a change in the 
approaches to identify trait-causing variants.  The three projects reported here cover a range 
of approaches.  Early studies focused on family-based data, using linkage analysis to find 
regions of the genome shared by members with similar trait values.  This approach was used 
to confirm the involvement of CYP2E1 with the level of response to alcohol in sibling pairs 
with an alcoholic parent.  With the advent of high through-put genotyping panels, the field of 
human genetics has shifted to population-based association studies that seek to find variants 
that correlate with a trait.  This approach was used to search for regions of the genome that 
infer risk for Pick’s disease, a spectrum of heterogeneous dementia diseases, and to 
reproduce the association with MAPT, a gene with known disease-causing mutations.  
Haplotype based analysis approaches have emerged to improve the analysis of genomic data.  
A novel algorithm for haplotype based analysis was developed to identify long haplotypes 
shared in a population based on genotypes from genome-wide association data and was 
found to be very accurate when predicting haplotypes within the shared regions.  Together, 
these three projects represent the past, present, and future of the study of human genetics. 
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Chapter 1 – Introduction 
 
The introduction to this dissertation outlines the purpose and significance of this study, 
defines the problem, and introduces the three projects covered in the chapters to follow. 
 
1.1 Purpose of the Study 
The study of the genetics of complex human traits seeks to identify genetic variants 
that predispose to the trait. Researchers expect that the identification of these genetic variants 
that predispose to disease traits will elucidate the pathogenesis of disease revealing possible 
targets for treatment.  Additionally, an understanding of disease provides insight into the 
genetics of normal biological processes.   
Mendelian traits have simple patterns of inheritance (e.g. autosomal dominant, sex-
linked recessive) and are influenced by a small number of genetic variants that have large 
effects.  In contrast, complex human traits have complex patterns of inheritance due to the 
effect of multiple genetic variants and gene-environment interactions.  Mendelian and 
complex traits can be vanishingly rare or common, but in the absence of a simple pattern of 
inheritance, the possibility of a genetic cause for a rare trait is generally not obvious.  
Typically in complex traits, an accumulation of variants combined with environmental 
exposures are needed to increase the risk for the trait to a level sufficient for that trait to  
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occur.  A continuum exists between complex and Mendelian traits in the number of causal 
variants and the effect size of the causal markers.  A trait that is common, with a larger 
number of causal variants that each contribute a small effect would have a complex pattern of 
inheritance, while a trait with a single causal marker that contributes the entire effect would 
have a Mendelian pattern of inheritance.  These patterns of disease characteristics can be 
used to optimize the study design and statistical approach used to identify possible genetic 
variants. 
To understand the genetic causes of a disease, genetic variants must be identified that 
occur in diseased or affected individuals.  Some studies take a candidate gene approach to 
identify these genetic variants, where previous evidence, such as the biology underlying the 
trait or previous genetic studies, is used to target the search on variants or genetic regions 
most likely to have a direct effect on disease.  However, for most diseases we do not 
completely understand the molecular processes leading to disease, making it difficult to 
identify possible variants likely to increase the risk for disease.  A genome-wide approach 
instead considers randomly chosen markers at a high density across the genome.  By 
systematically searching throughout the genome for regions with variants that are correlated 
with a trait or disease, we can identify genes likely to have an effect on the trait without 
requiring a previous hypothesis.   
The purpose of this dissertation was to search for genetic regions that increase risk for 
neurological phenotypes, specifically dementia and alcoholism, and to evaluate the 
development of a statistical application that seeks to aid in the identification of regions that 
influence a trait by considering haplotypes, or combinations of markers inherited together.  
Specific issues addressed by this study include the differences between linkage and 
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association analysis, locus heterogeneity, linkage disequilibrium, and haplotype phase 
inference.   
 
1.2 Overview and approaches to the problem 
Through the three projects that make up this dissertation, various statistical 
techniques were applied to different types of genetic data to find regions of the genome that 
affect a trait of interest.  The first two projects focus on techniques used to find regions of the 
genome more likely to occur in individuals with a certain trait or with extreme values of a 
trait.  A trait, often referred to as a phenotype, is a physical characteristic that can be reliably 
observed or measured.  It can be quantitative as in the case of a continuous measurement of 
height or qualitative as in the case of a dichotomous disease status.  The current dissertation 
addresses both kinds of traits—a project looking at the spectrum of responses to alcohol and 
a separate project concerning the disease status of various subtypes of dementia.  The final 
project deals with haplotype phase inference, a technique created as an intermediate step in 
the identification of regions containing possible causal variants able to deal with problems 
that obscure localization.  The combination of marker alleles on a single chromosome is 
referred to as a haplotype.  Haplotype phase inference seeks to statistically determine this 
combination of alleles from phase unknown SNP genotype data. 
Two approaches used to find correlation between a genetic variant and a phenotypic 
trait were applied to the projects in this dissertation.  The first uses linkage analysis which 
identifies regions that are shared “identical by descent” or inherited from a common ancestor.  
Regions shared more often in related individuals with similar trait values than expected by 
chance are likely to have an influence on the trait.  The second approach uses association 
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analysis to look for regions shared “identical by state.” Identity by state means the genotypes 
are the same in a population-based context but there is not enough information contained in a 
single genotype to determine whether it was inherited from a common ancestor.  Regions 
shared more often in a population with a certain phenotype when compared to a population 
without the phenotype are likely to have an influence on the trait.  These two approaches 
differ with regards to the study population, the type of markers measured, the statistical 
calculation approach, the localization of a causal variant, and the power to detect an effect. 
 
1.2.1 Linkage Analysis – study design and statistical approach 
A family based approach is utilized in linkage analysis to look for genetic regions 
shared between family members with the same trait ultimately identifying regions “linked” 
with a trait.  In a region containing a variant that has a direct effect on a trait, affected family 
members should share more genotypes identical by descent in the area surrounding that 
region than expected from chance based on their level of relatedness.  For example, we 
expect two siblings should share 50% of their genome by chance alone.  So if concordantly 
affected sibling pairs show enrichment for sharing in a particular region, something in that 
region likely has an effect on the trait.  For quantitative traits, siblings with less difference in 
their trait should share more alleles identical by descent in the region surrounding a causal 
locus and siblings with greater difference should share less.  Chromosomal regions where 
there is a correlation between the chromosome sharing and trait sharing are said to show 
evidence for linkage and the evidence for linkage can be aggregated across families.  DNA 
sequence variations, often called markers, are used to identify chromosomal regions.  
Markers are said to be informative in a family if the chromosomes in that family can be 
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distinguished by the sequence variations interrogated by the marker.  One class of sequence 
variants commonly used for linkage analysis has been the microsatellite marker. 
Microsatellites have short tandem repeats that commonly occur throughout the genome.  
These markers are highly polymorphic with multiple allelic forms that can easily be traced 
through families.   
While many statistical approaches are available for linkage analysis, in the linkage 
project that makes up part of this dissertation, a multipoint variance component approach 
implemented through the computer package SOLAR2 was used to find regions of the genome 
correlated with a quantitative trait.  Variance component linkage analysis is able to simplify 
the characterization of a trait by partitioning out the components that affect the trait.  The 
trait is modeled based on the linear function of Yi = µ+βjνij+gi+ei where µ is the population 
average of the trait, β a regression coefficient for the jth covariate, ν is the value of the jth 
covariate, g represents the additive genetic effects, and e the unmeasured environmental 
effects.1,3  The last two parameters can be estimated through the variance-covariance matrix 
represented by Ω=ΣΠσ2qi+2Φσ2g+Iσ2e+σ2cov where σ2qi is the additive genetic variance, Π is 
the estimated number of markers shared identical by descent, σ2g is the variance attributable 
to residual additive genetic factors, Φ represents the kinship matrix, σ2e represents the 
environmental factors, and σ2cov is the variance due to covariates.1,3  An added benefit to the 
variance component approach is opportunity for the inclusion of covariates and the 
possibility of identifying a covariate that can account for all of the variance in the trait and be 
classified as causal.  A covariate is a predictive variable that can influence a phenotype often 
independently from genotypic influences.  Covariates such as gender or age are included in 
the model to correct for the influences of these variables. In variance component linkage 
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analysis, the covariate parameter is modeled first, so if all of the variance can be attributable 
to an included covariate, there is no variance left for the other terms and the LOD score will 
be reduced to zero.  SOLAR considers a multipoint measurement of identity by descent, 
where markers from the entire chromosome influence the calculation but markers closest to 
the location of calculation are weighted more highly.  This provides more information than 
the standard two point calculation of IBD.  The evidence for linkage in a region is based on 
the calculation of a LOD score which compares the likelihood of a model assuming linkage 
with the basic polygenic model with no linkage.3   
 
1.2.2 Association Analysis – study design and statistical approaches 
Association analysis has quickly become a more suitable alternative to linkage 
analysis for investigation into the genetics of complex human traits due to advances in 
multiplex, high throughput genotyping technology and an improved understanding of 
common human population variation as a result of the International HapMap project.7  
Association analysis seeks to identify genetic changes that are identical by state, focusing on 
comparing an unrelated population of individuals with a trait (cases) with an unrelated 
population of individuals without a trait (controls).  If the measured allele of a certain variant 
occurs at a statistically different frequency in the population of cases compared with the 
population of controls, the variant is said to be “associated” with the trait.  The main genetic 
variant used in these studies is the single nucleotide polymorphism (SNP) which represents a 
single nucleotide change in the sequence of DNA.  By definition, a polymorphism is a 
genetic variant that has reached a relatively high frequency in a population (minor allele 
frequency of greater than 1%).  In practice, SNP genotyping is limited when the minor allele 
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frequency is less than 5% because the probability of detecting association is very low and 
often leads to spurious results.  SNPs are biallelic, meaning there are two forms present for 
each SNP in a population, often simplified to an A and B allele.  With only two forms, it is 
impossible to predict whether the alleles from a single SNP shared by two individuals are 
inherited from a common ancestor.  A single SNP provides less information than a 
microsatellite and many more are needed to provide enough power to detect a trait causing 
locus. To make up for the low information content in a SNP, high throughput genotyping 
technology has made it very cost effective to genotype markers throughout the genome with 
a much denser coverage than allowed by microsatellites.   
Two approaches were used to identify genetic regions associated with a trait.  The 
first was to apply a mixed linear model to genotypes from sibling pairs.  Since the dataset 
was family based, a correlation exists between related individuals but the mixed model 
method was able to account for the correlated family structure.10  This type of method 
considers both the correlation within families and the correlation between families to make 
statistical inferences about the genetic effects of a continuous trait.  This method was 
implemented through the PROC MIXED command in SAS.24  The approach is similar to the 
variance component approach of linkage analysis where there exists unknown random 
variables that can influence the variability of the trait.  The mixed model fits the data to a 
linear model of y=Xβ+Zγ+ε where y is the observed data, β represents the fixed effects 
parameters, γ represents random-effects parameters, and ε represents unknown random error.   
The second approach to measuring the level of association of genetic factors was 
through the calculation of a Fisher exact test to compare the genotype counts of AA, AB, and 
BB between populations of cases and controls.  The test is used to determine whether the 
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allele frequency in the cases is significantly different from the controls.  The Fisher exact test 
was chosen over a chi squared test due to the possibility of low allele counts for markers with 
small minor allele frequencies.  For the genome-wide association described in this 
dissertation, the fisher exact test for a two by three contingency table was approximated 
through the use of permutations.   
Genotype determination for the Pick’s disease project were made based on genotype 
calls generated using probe intensity levels from the Affymetrix genotyping chip.  A signal is 
generated after the hybridization of labeled DNA fragments with the complementary probes 
on the genotyping chip providing an intensity for each genotype measurement.  The signal 
intensity is normalized to correct for both the variation between features on a single chip and 
variation across different chips containing different samples ultimately generating a 
measurement corresponding to the amount of each allele in each sample.  These intensity 
measurements for the two alleles are transformed into Contrast (asinh(K(Sa-
Sb)/(Sa+Sb))/asinh(K)) and Strength log(Sa+Sb) which represent genotype and brightness 
respectively.  The constant K is termed the stretch factor and is used to increase the distance 
between genotype clusters creating a balance in the variability between the three clusters and 
allowing for improved differentiation.  The cluster membership of each sample is determined 
with the Mahalanobis distance defined as sqrt[(x-µ)2Σ-1(x-µ)] measured between each point 
and the cluster center.  The confidence score or call quality for each genotype measurement 
is determined based on the ratio between the closest cluster and the next to closest cluster.  
This approach to genotype determination is implemented in the BRLMM algorithm: 
Bayesian Robust Linear Model with a Mahalanobis distance classifier. 
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1.2.3 Genome-wide analysis – why should it work? 
In every diploid organism, two copies of each marker are typically present.  One is 
inherited from the maternal chromosome and one from the paternal chromosome.  The 
combination of SNPs on a single chromosome is referred to as a haplotype.  If every marker 
was truly independent, each SNP would need to be genotyped in order to capture all of the 
variation within the genome.  With 14 million validated SNPs cataloged in dbSNP5 this is not 
only unreasonable but also unnecessary.  There is statistical correlation between nearby SNPs 
since they are inherited together on a chromosome, referred to as linkage disequilibrium or 
LD.  Markers located closely together on a chromosome will more often be inherited 
together, while markers farther apart are more likely to be separated by recombination.  As a 
result, markers located in a region surrounding a causal variant will show association to the 
trait of interest even if the causal variant is not genotyped.6  This association will wane as the 
distance from the causal variant increases as there is less correlation due to the recombination 
that occurs though generations.   
Single marker association (considering a single SNP at a time) takes advantage of 
linkage disequilibrium to find an association with markers that may or may not have been 
directly genotyped.  The length of a region that is correlated or in complete linkage 
disequilibrium depends on the number of generations that have passed from the nearest 
common ancestor.  For a linkage study focusing on sibling pairs, that nearest common 
ancestor would be the parent, only one generation away.  But for association analysis, the 
nearest common ancestor may be hundreds to thousands of generations away.  Since shorter 
genetic regions are correlated this allows for a finer localization of the trait causing locus.  So 
after the identification of an associated marker, the region that could possibly contain a 
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causal variant is smaller and easier to systematically search through than a region provided 
by linkage analysis.  Patterns of LD in many world populations have been catalogued with 
the International HapMap project7 allowing for the creation of efficient SNP genotyping 
panels that can predict or “tag” nearby common variants based on the localized LD patterns 
inherent in each population.8   
Although markers or regions can be shown to be “linked” or “associated” with a trait, 
it provides little indication regarding causality.  Genome-wide analysis takes advantage of 
the linkage disequilibrium as described above to locate genetic regions that could contain 
causal variants. Most markers used in these studies have no effect on the amino acid 
sequence of a protein due to either the redundancy of the amino acid codons or that they lie 
in intergenic or intronic regions with no obvious connection with protein expression.  More 
often, the markers identified in genome-wide studies do not play a role in the trait, but 
instead represents genetic variation in the surrounding region that increases risk.6   
Perhaps the most important question regarding genome-wide analysis is not “Why 
should it work?” but instead “Why does it not work?”  The reality is that even though many 
studies are performed with the intention of understanding the genetic influences of disease, 
most of these studies provide inconsistent results because of unaccounted heterogeneity and 
poor power.  The final chapter of this dissertation details many of the problems facing 
genome-wide studies and why so many of them present conflicting results.   
 
1.2.4 Haplotype Analysis – The best of both worlds 
A number of algorithms have been created to apply statistical methods of linkage and 
association to different types of genotype data to solve genetic problems.  One option for 
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obtaining more information from genetic data is to consider multiple genotype measurements 
together.  While many genetic association studies focus on one marker at a time, these 
markers are inherited as a unit and interact in complex ways.  A haplotype refers to the set of 
alleles for nearby SNPs that are inherited together on a chromosome and the haplotype phase 
refers to the determination of a haplotype or the placement of alleles together along a 
chromosome.  The third project in this dissertation was performed to evaluate a novel 
algorithm created to determine haplotype phase on genome-wide association datasets and to 
understand the accuracy of this new method compared to standard haplotype phase inference 
programs. 
Haplotype based analysis seeks to find an association between the ancestral haplotype 
harboring a causal variant inherited by individuals with a trait of interest.9  When a mutation 
arises in an individual that causes a certain trait, it is contained on a chromosome and creates 
a new chromosome length haplotype.  As it is passed through to further generations of the 
population, the full length of the chromosome will be eroded away due to recombination.  
After many generations, individuals with that trait caused by the mutation started in the first 
individual, or founder, will have varying lengths of the original haplotype (or founder 
chromosome) surrounding the variant, assuming the mutation survives selection.9  The 
intersection of these haplotypes will map the trait-causing variant, usually to a finer region 
than by single marker analysis improving the probability of localizing a causal variant.   
Haplotype analysis combines the population based approach of association analysis 
with the search for regions identical by descent of linkage analysis.  While SNP genotyping 
represents common variation in the genome, haplotypic analysis allows for the consideration 
of untyped rare variants including those with low frequency or recent mutations that could be 
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hidden on a haplotype and not be “tagged” well by a single SNP on conventional genotyping 
panels.11  Considering multiple markers together as a haplotype provides a great deal of 
benefit to genetic association studies not only in terms of the power to detect an association 
with a trait, but also with the possibility for providing useful insights of the evolutionary 
history of human populations and complex patterns of linkage disequilibrium allowing for an 
understanding of natural selection, recombination rates, and patterns of migration.8,12   
 
1.2.5 Looking ahead 
When viewed together, the three main studies that make up this project represent the 
natural progression in the study of complex human disease, addressing issues relating to the 
ever-changing technological advances allowing for the measurement of more genetic units in 
larger sets of individuals and ways to understand the effect of multiple genetic units inherited 
as a haplotype.  Throughout the history of human genetics, early studies used linkage 
analysis to investigate sparse maps to identify variants that cosegregate with a trait through a 
limited number of generations within families.  As time progressed, the field has moved 
towards the consideration of dense genetic maps measured in large unrelated populations to 
understand the common causes of common disease through association analysis.  Going into 
the future, there is already a trend towards whole genome sequencing to allow for the 
consideration of all common and rare variants.  New scientific advances in genotype 
technology provide more information to add to our understanding of complex human traits, 
but also create more problems related to data management and ways to deal with 
confounding effects.  The last chapter of this dissertation provides a discussion about the 
future trends in the study of complex human disease. 
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1.3 Research Objectives 
The research objectives that constitute this dissertation are divided into three distinct 
projects.  While there is little overlap between the subject matters and analysis approaches, 
all three projects represent a continuum of the overarching methods for the study of the 
genetics of complex human disease. 
 
1.3.1 The investigation of CYP2E1 with the level of response to alcohol 
A genome-wide linkage study was performed to search for regions of the genome that 
confer risk to alcoholism as measured by the level of response to alcohol after an alcohol 
challenge.  Results from the genome-wide study led to the consideration of CYP2E1, a gene 
with known involvement with the metabolism of ethanol.  To further understand the 
relationship between CYP2E1 and the level of response to alcohol, both linkage and 
association analyses were applied to a combined map of microsatellite and SNP markers.  
Variance component linkage analysis supported the linkage shown at the end of chromosome 
10 from the original study.  However the addition of a second set of samples reduced the 
significance of the linkage signal.  An investigation of possible locus heterogeneity led to the 
discovery of a single family with unreliable phenotype data that was responsible for the 
reduction of signal.  Association analysis was performed on the SNPs genotyped in CYP2E1.  
The best evidence for association came from a marker upstream of the CYP2E1 promoter.  
Combined linkage and association was performed by including this associated marker as a 
covariate in variance component linkage, but this analysis was unable to definitively 
implicate the marker as a causal variant. 
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1.3.2 The association of the MAPT region with Pick’s complex diseases 
A genome-wide association analysis was performed on a number of different, but 
related neurodegenerative diseases collectively referred to as tauopathies due to the 
aggregation of tau proteins commonly found in diseased neurons.  Mutations had previously 
been identified in affected cases in the gene that encodes the tau protein, MAPT.  The MAPT 
gene is located on an inversion on chromosome 17 resulting in a high degree of linkage 
disequilibrium between markers across the inverted interval limiting the number of possible 
haplotypes.  A single haplotype, H1, was found to be overrepresented in certain subtypes of 
disease (specifically CBD and PSP).  The current genome-wide association study was able to 
replicate the overrepresentation of the H1 haplotype in PSP and CBD cases when compared 
to controls and show a constant high level of association for the inverted region for both PSP 
and PSP combined with CBD.  This positively replicated association provides increased 
confidence for the results generated from the GWAS in other regions of the genome (whole 
genome results not reported at this time). 
 
1.3.3 The evaluation of a novel algorithm for haplotype phase inference 
A novel haplotype phase inference algorithm called Convergent Haplotype 
Association Tagging, or CHAT, was created to determine the haplotype phase of a 
population of unrelated individuals genotyped for genome-wide association.  This new 
algorithm bases phase inference on the identification of subsets of individuals that share a 
region of the genome identical by descent allowing for the generation of a consensus 
haplotype for each region of sharing.  The complementary haplotype for each individual in 
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the subset can be easily identified and added to the set of known haplotypes.  The algorithm 
was created to outperform existing packages that tend to perform poorly across long regions 
and across recombination hotspots.  Reported is the evaluation of the novel phase inference 
algorithm compared to three publicly available phase inference packages.  Each algorithm 
was applied to simulated datasets created under different test conditions to understand how 
each program performs in regards to selection, degree of linkage disequilibrium, sample and 
marker size, and the imputation of missing genotypes.  CHAT demonstrated an improved 
single site error rate compared to the alternative haplotype phase inference algorithms and an 
improved switch error compared to ENT when considering a dataset with a large number of 
samples.  CHAT performed best with a larger number of samples but needs improvement in 
coverage to be able to compete with current haplotype phase inference programs and be 
practical for haplotype-based association mapping.   
 
1.4 Summary of the Chapter 
Chapter one introduced the research topic of this dissertation by briefly describing the 
problem facing the study of the genetics of complex human disease, discussing the 
techniques used throughout this dissertation for finding regions of the genome that confer 
risk to disease, and providing an overview of the three research problems covered in the 
following chapters.   
This dissertation will be organized into five chapters.  Chapter one presented the 
relevant background and introduced the three research projects.  Chapter two describes the 
combined linkage and association analysis performed as a follow-up to understanding the 
involvement of the gene CYP2E1 with the level of response to alcohol and thus the risk for 
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alcoholism.  Chapter three describes the results from a genome-wide association study on a 
number of related neurodegenerative diseases, focusing on the region containing MAPT 
which shows association with the two diseases that more commonly include aggregation of 
the MAPT protein product.  Chapter four describes the evaluation of a novel haplotype phase 
inference algorithm that bases phase inference on the identification of long haplotypes shared 
in a population and compares the accuracy of this algorithm with standard haplotype phase 
inference programs.  Chapter five provides a final discussion of the three research projects 
focusing on the limitations facing the detection of genetic variants that cause disease and 
future directions in the field of the genetics of complex human disease. 
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Chapter 2 - The investigation of CYP2E1 in relation to the level 
of response to alcohol through a combination of linkage and 
association analysis 
 
 
2.1 Abstract 
A low level of response to alcohol during an individual’s early experience with 
alcohol is associated with an increased risk for alcoholism. A family-based genome-wide 
linkage analysis using sibling pairs that underwent an alcohol challenge where the level of 
response to alcohol was measured with the Subjective High Assessment Scale (SHAS) 
implicated the 10q terminal region. CYP2E1, a gene known for its involvement with ethanol 
metabolism, maps to this region. Variance component multipoint linkage analysis was 
performed on a combined map of single nucleotide polymorphism (SNP) and microsatellite 
data. To account for the heterogeneity evident in the dataset, a calculation assuming locus 
heterogeneity was made using the HLOD (heterogeneity LOD) score. Association between 
SNP marker allele counts and copy number and SHAS scores were evaluated using a mixed 
model regression. Linkage analysis detected significant linkage to CYP2E1 which was 
diminished due to apparent locus heterogeneity traced to a single family with extreme 
phenotypes. In retrospect, circumstances recorded during testing for this family suggest that 
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their phenotype data are likely to be unreliable. Strong allelic associations were detected for 
several CYP2E1 polymorphisms and the SHAS score. DNA sequencing from families that 
contributed the greatest evidence for linkage did not detect any changes directly affecting the 
primary amino acid sequence. With the removal of a single family, combined evidence from 
microsatellites and SNPs offer significant linkage between the level of response to alcohol 
and the region on the end of chromosome 10. Combined linkage and association indicate that 
sequence changes in or near CYP2E1 affect the level of response to alcohol providing a 
predictor of risk for alcoholism. The absence of coding sequence changes indicates that 
regulatory sequences are responsible. Implicating CYP2E1 in the level of response to alcohol 
allows inferences to be made about how the brain perceives alcohol. 
 
2.2 Introduction 
While a number of phenotypic factors can affect the risk for alcoholism, one of the 
most studied endophenotypes is an individual’s level of response to alcohol during their early 
experience with alcohol.11 The level of response to alcohol can be reliably measured with the 
Subjective High Assessment Scale (SHAS) during an alcohol challenge or by the Self-Rating 
of the Effects of Alcohol (SRE) which uses recall to establish the number of drinks required 
to reach an effect. Children of alcoholics have a greater risk for alcoholism when they have a 
lower level of response.32,35,36 A low level of response established early in an individual’s 
drinking career can lead to higher future drinking levels.8,11,42 Populations at historically 
higher risk for alcoholism, such as Native American or Korean, need to consume larger 
amounts of alcohol to become intoxicated9,24,43 compared to those with lower risk28 who 
exhibit a more intense level of response to alcohol. Several studies have implicated genes 
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showing association with the level of response to alcohol (GABA, 5-HT, and KCNMA1).4,7,34 
The evidence proving association for these genes is weak by current standards that have been 
developed as a consequence from the technological advances enabling genome-wide 
association studies. Even though these genes may affect the level of response to alcohol to 
some degree, it is possible that these reported associations reflect the typical reporting bias 
seen in candidate gene studies.  
Initially, data were collected from 139 sibling pairs.46 Variance component analysis 
found a significant LOD (Log of Odds) score peak of 3.2 for the SHAS score at the 10q 
terminal region. Of the genes located at 10qter, CYP2E1 has a known involvement with 
ethanol metabolism. The CYP2E1 enzyme metabolizes ethanol and acetaminophen, as well 
as many toxicologic and carcinogenic compounds and can be induced by ethanol and 
nicotine.39 In the second stage of the study, when 99 newly collected sibling pairs were 
added,34 the peak at 10qter was significantly diminished. As will be described in this paper, it 
was initially assumed that the diminishment was due to locus heterogeneity, but ultimately 
the reduced evidence for linkage was explained by a single family with extreme and 
unreliable phenotypes. 
Most of the ethanol that is consumed is oxidized by the liver using alcohol 
dehydrogenase (ADH). At the high concentrations associated with chronic alcohol 
consumption, metabolism of ethanol to acetaldehyde increases while the subsequent 
conversion into acetate is decreased, leading to even higher levels of acetaldehyde. It was 
shown in rats that chronic consumption reduced the oxidation of acetaldehyde in the liver, 
thus providing an explanation for the high blood acetaldehyde levels measured after chronic 
use in human subjects.19 Acetaldehyde is toxic and highly reactive,50 binding to nearby 
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proteins thus creating an antibody response, decreased DNA repair, and glutathione depletion 
ultimately reducing the ability of the liver to clear free radicals.20 As a result from the 
oxidation, NAD+ is reduced with the addition of an electron to form NADH50 used by 
mitochondria for ATP synthesis. At high concentrations, ethanol is oxidized by ADH at a 
higher rate leading to an increase in the NADH/NAD+ ratio.50  
CYP2E1 is part of the Microsomal Ethanol Oxidizing System (MEOS) accounting for 
up to 10% of ethanol oxidation in the liver.39 Once the ADH pathway becomes saturated due 
to high ethanol concentrations, the MEOS pathway activity increases.20 By the MEOS 
pathway, CYP2E1 metabolizes ethanol and other substrates into toxic metabolites creating 
free radicals in the form of reactive oxygen (O2) intermediates creating oxidative stress 
leading to liver damage. CYP2E1 uses O2 to oxidize ethanol to aldehyde and NADPH to 
NADP+. While generally used biosynthetically, NADPH can be regenerated from NADP+ 
with the conversion of NADH to NAD+. In the absence of NADPH, oxidation of ethanol to 
aldehyde by CYP2E1 results in superoxides.50 An excess of reduced NADH in addition to 
the increased activity of hydrogen shuttles in mitochondria, results in an increased intake of 
electrons leading to an increase of superoxide anions.37 The increased creation of Reactive 
Oxygen Species, or ROS, as a result from the shift in cellular redox state, coupled with the 
reduced ability to clear these free radicals, due to the increase in acetaldehyde, is thought to 
be a major driving force in the development of alcohol related liver disease.  
The catalase pathway can oxidize ethanol in conjunction with hydrogen peroxide 
generating systems, such as NADPH oxidase.50 The catalase pathways plays a larger roles in 
the oxidation of ethanol in the brain, where little ADH oxidation occurs.50 In a study by 
Vasiliou et al.,40 it was found that animals with a knockout of either catalase or CYP2E1 
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were more sensitive to the sedative effects of ethanol than control, wild-type animals. The 
study found that CYP2E1 did not contribute significantly to ethanol clearance in the brain, 
but was instead involved with ethanol processing in the brain affecting sensitivity. 
High ethanol concentrations can interfere with the ability of CYP2E1 to metabolize 
other substrates due to competition from the shared oxidation pathway leading to reduced 
drug clearance and elevated drug concentrations.39 The interaction of certain drugs with 
alcohol will lead to a long-lasting, enhanced drug effect, often leading to overdose. A similar 
relationship is thought to exist with nicotine. It has been shown that smokers have a more 
rapid ethanol clearance than non-smokers, suggesting a biological basis for the correlation of 
tobacco and alcohol consumption seen in alcoholics.33  
A number of polymorphisms in CYP2E1 have been tested in relation to alcoholism 
and a number of related disorders, including many types of cancer, with varying, often 
conflicting, results. Carriers of the c2 allele of CYP2E1*5B have increased risk for alcoholic 
liver disease and are more likely to consume excessive amounts of alcohol possibly due to 
the higher transcriptional levels of CYP2E1 seen with this allele.10,30,44 Variants in the gene 
have been implicated in the increased risk of different types of cancer relating to the 
respiratory and digestive systems.5,21,49  
Due to the previously described relationship between CYP2E1 and the metabolism of 
ethanol and positive linkage results concerning the level of response to alcohol in relation to 
alcoholism, a number of single nucleotide polymorphisms (SNP) were genotyped in the 
CYP2E1 to further elucidate the gene’s role in alcohol response. Both genotype and copy 
number were tested for association with the level of response to alcohol as measured by the 
  23
SHAS questionnaire. Combined linkage and association analysis was performed to determine 
whether a single marker or haplotype could account for the linkage signal seen at 10qter.  
 
2.3 Methods  
2.3.1 Alcohol Challenge 
The data collection protocol was approved by the Human Subjects Protection 
Committee at the University of California in San Diego and used written, informed consent. 
The design for the alcohol challenge is fully described in the initial report by Wilhelmsen et 
al..46 Male and female subjects ranging in age from 18 to 29 years old were recruited from a 
population of college students. Chosen sibling pairs reported having an alcohol dependent 
parent, but were not alcohol dependent themselves. The siblings included 43.7% males and 
56.3% females. They had an average age of 22.4 years and 14.2 years of education. 72.2% 
were Caucasian, 20.0% were Hispanic, and 7.8% were African-American. For 85.0% of the 
subjects, the alcohol-dependent parent was the father, whereas for 4.4% it was the mother, in 
4.0% it was both parents, and in 6.6% the more intensive interview revealed that neither 
parent met full criteria for dependence.  
To measure each participant’s response to alcohol, the Subjective High Assessment 
Scale (SHAS) questionnaire was administered. For the challenge, each subject was given 8 
minutes to consume a 20% by volume solution of 95% ethanol, at 0.75 ml/kg for women and 
0.9 ml/kg for men. Baseline levels for each score (SHAS, body sway, and breath alcohol 
level) were measured prior to the challenge and then were measured at multiple set time 
intervals throughout the 3 hour challenge. Ultimately the changes in SHAS score and body 
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sway at 1 hour after the challenge were used as phenotypes for the genome-wide genetic 
analysis. Genotyping was performed on 811 microsatellite markers across the genome.  
 
2.3.2 Taqman Genotyping 
Genomic DNA was extracted from whole peripheral blood samples. Genotyping was 
performed on 10 SNPs with Taqman genotyping assays using locus specific PCR primers 
and fluorescent allele specific probes designed by Applied Biosystems. Standard Taqman 
protocol was followed and endpoint amplification intensity was measured by the 7900 ABI 
Sequence Detector. The position of the genotyped markers in relation to CYP2E1 can be 
found in Figure 2.1. The HapMap Consortium reported three major haplotypes in the 
Caucasian population, as seen in Figure 2.1, which could be distinguished by the initial two 
SNPs that were genotyped. Table 2.1 lists the names and positions of the genotyped SNPs. 
 
2.3.3 Copy number analysis 
The copy number of CYP2E1 was determined for each sample in quadruplicate 
through the amplification of both a probe specific to CYP2E1 and a standard probe by real-
time PCR using the standard Gene Dosage protocol provided by Applied Biosystems.22 
Preliminary amplification showed the two probes used for analysis had different efficiencies 
of amplification, which was corrected by a standard dilution curve added to each plate. The 
fold increase after n number of cycles was calculated by (efficiency)n and the ratio of this 
increase between the target and reference genes provided copy number. Standard copy 
number quantification assumes equal amplification efficiencies, but this is not always a valid 
assumption. Correcting for even small differences in amplification efficiencies leads to less 
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variability among the quadruplicate samples and lowered standard error in overall copy 
number determination. 
 
2.3.4 CYP2E1 resequencing 
Index cases from the 96 families with the greatest evidence for linkage to the 10q 
terminal region were selected for resequencing. Each coding sequence exon was resequenced 
using primers from Applied Biosystems using the standard provided procedure. 
 
2.3.5 Linkage allowing for heterogeneity 
A map of the positions of the genotyped SNPs relative to the microsatellite markers 
was created with Fastlink. Variance component methods were used to recalculate LOD 
scores using SOLAR v4.0.7 with the identity by descent provided through pedigree 
information and estimating multipoint identity by descent sharing probabilities.2 Variance 
component linkage analysis uses correlation in the phenotype to partition out variance 
between relative pairs into the effects of the genes in the region of interest, additive genetic 
effects of other genes, and non-shared environmental variance. The trait is modeled based on 
the linear function of Yi = µ+βjνij+gi+ei where µ is the population average of the trait, β a 
regression coefficient for the jth covariate, ν is the value of the jth covariate, g represents the 
additive genetic effects, and e the unmeasured environmental effects.2  The last two 
parameters can be estimated through the variance-covariance matrix represented by 
Ω=ΣΠσ
2
qi+2Φσ2g+Iσ2e+σ2cov where σ2qi is the additive genetic variance, Π is the estimated 
number of markers shared identical by descent, σ2g is the variance attributable to residual 
additive genetic factors, Φ represents the kinship matrix, σ2e represents the environmental 
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factors, and σ2cov is the variance due to covariates.2  The evidence for linkage in a region is 
based on the calculation of a LOD score which compares the likelihood of a model assuming 
linkage with the basic polygenic model with no linkage.2  To account for the heterogeneity 
evident in the dataset, a calculation assuming locus heterogeneity was made using the HLOD 
(heterogeneity LOD) score to identify the cause of the lowered peak at the end of 
chromosome 10 observed after the addition of samples to the dataset.  
 
2.3.6 Association analysis 
Association between SNP marker allele counts and copy number and SHAS scores 
were evaluated using a mixed model regression through the SAS statistical package testing 
for statistical inferences using a generalization of the standard linear model. The mixed 
model fits the data to a linear model of y=Xβ+Zγ+ε where y is the observed data, β 
represents the fixed effects parameters with design matrix X, γ represents random-effects 
parameters with design matrix Z, and ε represents unknown random error.  Family ID and 
marker genotype were used as classification variables and the effects of copy number and 
genotype were modeled against the SHAS score. Genotypes were classified based in the 
count of the minor frequency allele. 
 
2.3.7 Combined Linkage and Association 
Combined linkage and association analysis using SOLAR v4.0.7 was performed to 
include identity by state information similar to the approach used by Almasy et al.1 where the 
variance in the SHAS score that cannot be accounted for by the covariate parameter based on 
the number of minor alleles was decomposed into the standard variance components. To see 
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whether the linkage signal could be explained by the allele effects of a single SNP, each SNP 
marker was individually tested by including the number of minor alleles as a covariate. 
Polygenic covariate screening was used to calculate the significance level after the inclusion 
of any particular SNP and multipoint analysis was used to calculate the multipoint LOD 
score for the SHAS score.  
By combining linkage and association approaches, a disease loci position can be 
confined to a region finer than linkage analysis alone and avoid false positive association 
results due to admixture. Assuming the linkage is not over-estimated, if a measured variant is 
the actual functional variant affecting the phenotype and no other variants nearby confer any 
additional risk, linkage analysis conditional on the genotype of such a variant should provide 
no evidence for linkage. However if the suspected variant is in some degree of linkage 
disequilibrium with the actual causal variant, the evidence for linkage will be reduced 
proportional to the degree of LD. 
 
2.4 Results 
With a combined map of microsatellite and SNP markers the dataset was reanalyzed, 
as described in the original linkage study,34,46 using SOLAR. When divided into the two 
stages of sample sets from the previous study, significant linkage was found in stage 1 
samples with a peak LOD score of 3.14; however, when combining the initial 139 sibling 
pairs with the additional 99 sibling pairs in stage 2, the linkage signal lowered to a peak LOD 
score of 1.61. The LOD score plot can be seen in Figure 2.2.  
Multipoint linkage analysis allowing for locus heterogeneity was performed for the 
SHAS phenotype using microsatellite and SNP data from 10qter. The family specific 
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heterogeneity score (α) and LOD score was inspected for each family. Most of the families 
had α scores of 0.99, one family stood out with an α of 0.37 indicating poor support for 
linkage to the region. The individual pedigree LOD score for this family alone was -0.97 
accounting for most of the reduction in LOD score seen between stage 1 and stage 2. Based 
on the level of alleles shared between siblings in this family, it was expected that these 
siblings should have more similar SHAS scores. The sibling pair had a large difference in 
phenotype despite having inherited the same chromosome Identical By Descent from both of 
their parents (IBD of 2). While one sibling reported a SHAS score of 26.75 (z = 2.147), the 
other reported a SHAS score of 4 (z = -0.7161).  
Comments from the observers of the study propose phenotyping error as the cause of 
the extreme phenotype difference. The more sensitive sibling felt nauseated during the 
challenge. This is a common response reported by many subjects, and the SHAS score for 
this individual is around the same value reported by other individuals with a similar response. 
The other sibling, with SHAS scores indicating they were insensitive to alcohol, had a blood 
alcohol level close to the predicted value, indicating that they were appropriately dosed. This 
sibling fainted briefly during blood draw. The researchers involved in testing these subjects 
take special care to avoid fainting and report that it only happens 2% of the time. Although 
the subject woke up quickly and admittedly felt fine, this fainting spell could have 
contributed to the low response indicated by a low SHAS score. Therefore it is likely that the 
reduction in LOD score by the inclusion of the discordant family is due to a phenotyping 
error. While the inclusion of this family has dramatic effect on the linkage analysis it has a 
negligible effect on the association analysis. Due to irregularity from the reported testing, the 
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whole family was removed from analysis. When the single family was removed, the original 
LOD score peak was reestablished with the maximum LOD score for 10qter at 3.40. 
SNP genotypes could not be called automatically using the manufacturer supplied 
program due to copy number differences which affected the allele signal intensities causing 
samples to fall between the heterozygous and homozygous genotypes. Genotype calls were 
made manually, assuming that the intermediate samples were either AAB or ABB depending 
on the location relative to the heterozygote cluster. The best estimate of copy number and 
genotype was made by integrating the real-time PCR measured copy number, Taqman 
derived genotype and pedigree structure. While the majority of subjects (85%) have 2 copies, 
11% had 3 copies, and 4% had 1 copy. A small number (<2%) were considered to have 
greater than 3 copies based on real time PCR, but these measurements were not considered 
plausible based on Taqman derived genotype and pedigree information.  
Mixed model regression analysis which controlled for the relatedness of subjects 
within families was used to investigate the association between copy number genotype and 
level of response to alcohol. Copy number had little effect on the level of response to alcohol. 
The presence of at least one copy of a relatively rare allele for several SNPs is associated 
with a more intense response to alcohol. The best evidence for association was found for the 
first three markers, which lie near the beginning of the gene near the promoter region, when 
considering genotype alone. The SNP rs10776687 showed the greatest evidence for 
association with a p value of 0.007 and an odds ratio of 2.893 (1.476-5.669 95% CI). Odds 
ratios for all other SNPs were not significant. In this case, copy number was ignored and all 
genotypes were assigned as biallelic. When considering copy number and genotype together, 
none of the markers were significant. Copy number alone (1, 2, or 3) was not significantly 
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associated. Interestingly, when modeling the effect of genotype and copy number on the 
number of cigarettes smoked per day, copy number of CYP2E1 was associated with this 
smoking phenotype with an average p value of 0.014. Association p values for the regression 
analysis are shown in Table 2.2. 
Intuitively we would expect that inclusion of a causal SNP as a covariate would 
reduce the residual linkage due to IBD to zero,1 but this is an area of active research. After 
each SNP marker was separately tested in the variance component model, it was found that 
inclusion of the number of minor alleles of any single SNP was not able to explain all 
variation in the SHAS phenotype. When considering the dataset after removing family 44, 
the peak LOD score was 3.36. The marker that lowered this LOD score the most (by 1.21 
LOD units) when included as a covariate was rs10776687, the marker located closest to the 
linkage peak. Other SNPs lowered the LOD score by lesser amounts, as seen in the Table 2.3 
below. Combined linkage and association analysis indicates that no single locus tested is 
likely to be the only causal allele. When testing haplotypes, none of the three haplotypes 
were able to completely account for the linkage signal. 
In addition to testing SNP markers to determine whether a single SNP could directly 
influence the SHAS phenotype, a number of smoking and drinking phenotypes were 
analyzed by including them as covariates when modeling their relationship with SHAS. 
Three of these phenotypes (average number of cigarettes per day, the maximum amount 
drank in one day, and the average number of drinks consumed on days the subject consumed 
alcohol) improved the overall peak LOD score compared to the model without covariates. 
The other tested phenotypes (number of days the subject drank in the last week, amount 
consumed 24 hours prior to challenge, number of days of smoking in a month, and number of 
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cigarettes smoked on days where the subject smoked), lowered the peak LOD score 
presumably because these phenotypes are correlated with the SHAS score. All LOD scores 
are shown in the Table 2.4 below.  
To examine whether previously unidentified missense sequence changes could be 
responsible for the association detected, coding sequence exons were resequenced for 96 
index cases from the families with the strongest evidence of linkage. No missense changes 
were found and no novel polymorphisms were identified. 
 
2.5 Discussion 
Alcoholism is a complex disease with potentially many genetic influences. 
Investigators have tried to minimize heterogeneity by choosing a narrowly defined phenotype 
such as the level of response to alcohol that was measured with the SHAS score in this study. 
Strong evidence for linkage to 10qter was observed for the SHAS score in subjects from an 
alcohol challenge only after the removal of one family that retrospectively should not have 
been included in the analysis. After linkage was found at the end of chromosome 10, several 
SNPs genotyped in CYP2E1 were associated through mixed model regression with the level 
of response to alcohol as reported by the SHAS score. Copy number did not appear to affect 
the SHAS score even though copy number differences were found between individuals 
across the CYP2E1 gene.  
When considered separately, linkage was found over the region containing CYP2E1 
and SNPs from the gene were found to be associated with the SHAS score. If inclusion of the 
causal variant as a covariate in variance component analysis always reduces the residual 
LOD score to zero, we were unable to implicate a causal variant directly influencing the level 
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of response to alcohol in the families studied. It is possible that an unidentified 
polymorphism nearby could play a causal role in the level of response to alcohol as the 
degree of signal reduction is largest in the marker closest to the linkage peak and then 
declines for markers farther away. Another possibility is that a single marker cannot account 
for the entire linkage signal because many markers in the region play a role in the response. 
Instead of a single polymorphism causing variation, combinations of polymorphisms across 
the region may work together to contribute to the variation seen in our dataset. Support from 
the heterogeneity LOD score calculation showing that all families showed evidence for 
linkage combined with the independently derived association analysis imply that the LOD 
score peak was not over-estimated. It still can be concluded the regulatory sequences near 
CYP2E1 appear to play a role in the level of response to alcohol. 
Variance component linkage analysis for the level of response to alcohol was 
significantly affected by including covariates for recent drinking and smoking behavior. 
Since CYP2E1 expression is inducible by alcohol and nicotine,15 this further supports the role 
of CYP2E1 in level of response to alcohol. CYP2E1 represents a metabolic intersection 
between these substances of abuse.33 It was initially surprising that while an association was 
not found between the level of response to alcohol and copy number of CYP2E1, an 
association was found between nicotine use and copy number. Studies have shown that 
neither ethanol nor nicotine increase the level of CYP2E1 mRNA in rat hepatic tissue.12 
Ethanol likely changes the activity of CYP2E1 by interacting with the active site leading to 
increased protein stabilization and reduced clearance by degradation. Given that the 
induction of CYP2E1 by nicotine requires multiple doses and does not interact with the 
catalytic function of CYP2E1, it is thought that the mechanism behind nicotine induction is 
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not through protein stabilization.26,33 Since the molar concentrations are vastly different it is 
unlikely that both nicotine and alcohol could stabilize CYP2E1 by the same mechanism. 
Since ethanol and nicotine likely induce CYP2E1 through different mechanisms, these two 
drugs may have an additive effect on CYP2E1 induction and function.33 The ability to induce 
CYP2E1 activity by nicotine, but not alcohol, could be dependent on basal transcription rates 
that could be affected by gene copy number.  
The four polymorphisms commonly tested in CYP2E1, CYP2E1*5B (c2), CYP2E1*6 
(C), CYP2E1*1B (A1), and CYP2E1*1D (1C), have been found to be associated with 
alcoholism and related disorders in a number of studies. Several of these variants are rare in 
the Caucasian population (see below). Carriers of the c2 allele of *5B have often been found 
to have increased risk for alcoholic liver disease.10 possibly due to the increased tendency to 
consume excessive amounts of alcohol.30 The C allele of *6 was shown to be associated with 
the predisposition for alcoholism in Japanese men.14 The A1 allele of *1B was found to have 
a significantly higher allele frequency in alcoholics than in nonalcoholic individuals from a 
Mexican Indians population.27 The 1D variant allele was shown to be associated with 
elevated CYP2E1 activity after alcohol consumption.25 For every association found with 
CYP2E1 variants, a number of studies found no association between the variants and alcohol 
consumption or risk of alcoholism which could be due to differing phenotype categorization 
or population allele frequencies.6,13,29,31,41  
Of the markers measured in the current study, the most associated SNP with level of 
response to alcohol, rs10776687, is in complete linkage disequilibrium (LD) with the c1 
allele of CYP2E1*5B, rs2031920, implying that this marker is associated with the level of 
response to alcohol as well. A homozygous genotype of the minor allele c2 of CYP2E1*5B 
  34
is associated with an increase in gene transcription.44 Another marker, rs2515641, is in 
complete LD with rs2070676, also known as CYP2E1*1B.  
As CYP2E1 is involved with the metabolism of many carcinogenic compounds, it is 
not surprising that variants in the gene have been implicated in a number of different types of 
cancer. The generation of ROS as a result of CYP2E1 oxidation will lead to the creation of 
lipid peroxidation products such as 4-hydroxynonenal which reacts with DNA to form DNA 
adducts leading to highly mutagenic cells resistant to apoptosis.6 The metabolism of 
procarcinogens by CYP2E1 commonly found in alcohol, tobacco, and industrial chemicals 
can be enhanced through chronic ethanol.3  
While a number of CYP2E1 variants have been analyzed in relation to cancer 
development, CYP2E1*5B is most often considered. Many of these associations are 
enhanced by alcohol or nicotine intake which further supports the role of CYP2E1 in the 
metabolism of these substances. The c1/c1 genotype of the CYP2E1*5B variant increased 
risk of hepatocellular carcinoma in smokers from a Taiwanese population49 and oral cavity 
cancer in heavy smokers from Caucasians and African Americans populations.21 Conversely 
other studies have found evidence for the minor c2 allele leading to an increased risk of 
hepatocellular carcinoma in ethanol users with chronic liver disease and oral cavity cancer in 
combination with heavy drinking.5 Others have found no association between the 
CYP2E1*5B variant and the same types of cancer including a number of studies for 
hepatocellular carcinoma.17,18,47 Many CYP2E1 association studies did not detect an 
association because the c2 risk allele is rare in Caucasians (2-3%)17,29 and African Americans 
(0.3-7% ),17,23,48 but much more common for Asian (24-30%)18,38,45 and Mexican American 
populations (15%).48  
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In aggregate it appears that alleles that increase CYP2E1 expression increase level of 
response to alcohol and risk for cancer, presumably by allowing the activation of 
procarcinogens or the production of ROS. Previous evidence for the involvement of CYP2E1 
with alcohol metabolism and the incidence of several alcohol related cancers, strongly 
supports the conclusion that CYP2E1 alleles are associated with the level of response to 
alcohol and ultimately the development of alcohol use disorders. With multiple lines of 
evidence linking CYP2E1 to alcohol intake and subsequent outcomes, this gene can be an 
important predictor of risk for alcoholism and provide us with a better understanding of how 
the brain perceives alcohol. Drugs that affect the expression of this gene and, subsequently, 
the perception of alcohol, could reduce intoxication or limit consumption and thus moderate 
the development of alcoholism. 
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Figure 2.1 Location of genotyped SNPs in relation to CYP2E1 on chromosome 10. 
Figure 2.1 The top of the figure shows the position on chromosome 10 with each SNP 
location indicated by triangles. The middle part of the figure shows the position of CYP2E1 
with exons represented as yellow rectangles and introns as the lines between. At the bottom, 
phased haplotypes derived from the HapMap Caucasian (CEU) population are shown. Each 
vertical block represents a SNP genotyped in HapMap. Not all of these markers were 
genotyped in the study, so vertical black lines through the haplotype figure indicate actual 
genotyped SNPs.  
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 Figure 2.1 
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Figure 2.2 LOD score plot showing linkage in the region surrounding CYP2E1.  
Figure 2.2 Shows the LOD score plot highlighting the linkage near CYP2E1. The line labeled 
as First Set represents the initial 139 sibling pairs. The line labeled as Second Set represents 
the complete set of 238 sibling pairs. Once the family with questionable phenotypes was 
removed, the strength of the linkage signal was restored to the level provided by the First Set 
samples. Locations of microsatellite markers and SNPs are shown on the X-axis. 
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Table 2.1 Translation of identification values for genotyped SNPs and position 
 
rs ID ABI Assay ID 
Build 129 
position 
(bp) Other names 
rs10776687 hCV2431881 135184332  
rs9418990 hCV2431878 135187956  
rs2070673 hCV2431871 135190557 CYP2E1*7_-333T>A 
-- hCV30633979 135192024 CYP2E1*2,g.1132G>A 
rs943975 hCV7468406 135192250  
rs6413421 hCV25594214 135195801  
rs915909 hCV7468401 135197387 CYP2E1_6498C>T(I321I) 
rs2515641 hCV16026002 135201352 CYP2E1_10463T>C(F421F) 
rs2480258 hCV2431850 135202090  
rs2249695 hCV2431848 135202158  
 
Table 2.1 A listing of the various identification names for the SNPs genotyped in the study 
based on the Applied Biosystems ID. Included under “other names” are names commonly 
used for specific markers. 
 
Table 2.2 Association p values for logistic regression analysis between the SHAS score 
and CYP2E1 genotype alone or genotype considering copy number.  
 
 Genotype Genotype considering copy number 
Minor 
allele 
frequency 
rs10776687 0.007 0.103 0.056 
rs9418990 0.024 0.125 0.244 
rs2070673 0.015 0.077 0.238 
hCV30633979 0.215 0.253 0.004 
rs943975 0.182 0.274 0.131 
rs6413421 0.133 0.123 0.057 
rs915909 0.058 0.081 0.007 
rs2515641 0.45 0.261 0.176 
rs2480258 0.04 0.187 0.252 
rs2249695 0.024 0.139 0.268 
 
Table 2.2 Logistic regression was used to test for association between the genotyped SNPs 
and the SHAS quantity representing the level of response to alcohol. P-values < 0.05 are in 
bold. The three markers near the 3’ end and two from the 5’ end were most associated with 
the level of response to alcohol. The best evidence for association came from the initial SNP, 
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rs10776687. None of the SNPs were associated when the genotype call was made considering 
copy number. 
 
Table 2.3 Results of variance component linkage analysis for combined linkage and 
association.  
 
Covariate 
LOD 
score covar p Variance  
None 3.36   
rs10776687 2.15 4.25E-04 0.0531 
rs9418990 2.46 5.65E-03 0.021 
rs2070673 2.54 5.04E-03 0.0311 
rs943975 2.23 8.74E-02 0.0105 
rs2515641 2.88 5.30E-02 0.0076 
rs2480258 2.42 1.26E-02 0.0268 
rs2249695 2.54 9.58E-03 0.02 
 
Table 2.3 Combined linkage and association analysis showed that a single marker was unable 
to account for all of the variation in the signal. This was accomplished by adding each SNP 
individually into the model as a covariate. With no covariates, the LOD score was 3.36. The 
SNP that lowered the score the most when added as a covariate was rs10776687and was able 
to explain 5.3% of the variance in the SHAS score. 
 
Table 2.4 Results of variance component linkage analysis with the inclusion of several 
drinking and smoking covariates 
 
 
covariate 
LOD 
variance 
number of days in the last week where subject drank 2.19 0.078 
amount consumed in the last 24 hours 2.82 0.028 
days smoking per month in previous 6 months 3.03 0.046 
cigarettes per day, on smoking days in previous 6 months 3.27 0.036 
Average number of cigarettes per day 3.37 0.026 
maximum amount drank in one day 3.47 0.084 
Average number of drink on days they drank 3.77 0.066 
 
Table 2.4 A number of smoking and drinking phenotypes were analyzed by including them 
as covariates when modeling their relationship with SHAS. Three of these phenotypes 
(average number of cigarettes per day, the maximum amount drank in one day, and the 
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average number of drinks consumed on days the subject drank) improved the overall peak 
LOD score compared to the model without covariates. 
  
 
Chapter 3 - The role of the Tau gene region chromosome 
inversion in PSP, CBD and related disorders 
 
 
3.1 Abstract 
A genome wide association scan was performed to search for variants that confer 
susceptibility to 4 tauopathies and clinically related disorders.  This paper focuses on the 
results from an inverted region of chromosome 17 that contains the MAPT gene.  A total of 
231 samples were genotyped on the GeneChip 500K Affymetrix SNP arrays.  Missing or 
untyped SNPs were imputed with IMPUTE from the Chiamo suite.  Genotypes of cases and 
controls were compared with a Fisher exact test on a marker by marker basis.  Haplotypes 
were determined by the visual inspection of genotypes.  Cases of PSP, CBD, FTD, and FTD 
with amyotrophy were collected from an unrelated Caucasian population.  Unaffected 
individuals from the same population were used as controls.  The samples included in the 
study were collected by the Memory and Aging Center at UCSF or by KCW.  For the 
comparison between any particular disease and controls, the association was constant across 
the interval.  Significant associations were seen for both PSP and PSP combined with CBD.  
Of the two haplotypes seen in the region, the H1 haplotype was overrepresented in PSP and 
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CBD cases when compared to controls.  The association found in these tauopathies across 
this interval on chromosome 17 further supports the theory that one or more susceptibility 
loci in this region is affecting susceptibility specifically to PSP and CBD.  Since the markers 
are highly correlated and the association is seen across the whole region, it is difficult to 
narrow down a disease causing variant or even a possible candidate gene.  However 
considering the pathology of these diseases and the involvement of tau mutations seen in 
familial forms, the MAPT gene represents the most likely cause driving the association.   
 
3.2 Introduction 
The Pick Complex refers to a spectrum of diseases with a variety of overlapping 
clinical and pathological features, due to a related genetic etiology.  A common, though not 
ubiquitous, overlapping feature of these diseases is the presence of tau protein inclusions, or 
aggregates.  Thus, the genetics and brain histochemistry of the gene that encodes for tau, 
microtubule associated protein tau (MAPT), provides a compelling reason for thinking that 
patients with these clinically and pathologically diverse findings should be thought of as a 
contiguous group. These diseases are characterized clinically by cognitive, behavioral, and 
movement defects.  This study focused on four diseases in the spectrum where tau 
histochemistry and genetics are believed to be critical—progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD) with or without 
amyotrophy.   
The clinical signs and symptoms observed in patients with these diseases are 
correlated with the anatomic distribution of neuronal loss, which can be quite variable.  There 
are several patterns of inclusions of insoluble proteins in affected individuals, but there is 
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only limited correlation between inclusion type and clinical symptomatology.  Pick Complex 
diseases can be accompanied by tau inclusions, ubiquitin inclusions, or no inclusions at all.15  
Pick Complex diseases that contain tau inclusions are collectively referred to as tauopathies.   
Many families with inherited tauopathies have been linked to the same genomic 
region, and collectively, these families are said to be affected with frontotemporal dementia 
and parkinsonism linked to chromosome 17 (FTDP-17).8  MAPT was considered to be a 
likely candidate gene in this region for its involvement in FTD with tau inclusions, and 
subsequently, many MAPT mutations have been identified in affected individuals.  A variety 
of Tau mutations have been identified that affect protein function by either creating changes 
in level of translated protein or by alternative RNA splicing, which may upset the interaction 
between tau and microtubules, allowing unbound and abnormally phosphorylated tau to 
polymerize into inclusions.5  Different tau mutations alter biochemical properties of the gene 
product, but these mutations do not necessarily predict the exact clinical nature of the 
disease.  The same mutation in affected individuals, even in the same family, may result in a 
different age of onset, combination of symptoms, and clinical diagnosis.13  The variable 
morphology of accumulated tau proteins could be explained by the wide range of mutations 
that have been found in these diseases.  In various tauopathies, the inclusions may differ 
based on the ratios of particular isoforms and the physical location of accumulation.  At least 
40 MAPT mutations have been identified in patients with FTD and related diseases.12  Tau 
inclusions, usually without MAPT mutations, are part of the pathologic definition of CBD 
and PSP while cases of FTD are often seen without tau mutations or tau inclusions.  Another 
set of cases with FTDP-17 that contain ubiquitin inclusions, but no tau inclusions, was linked 
to the same region on chromosome 17.9  Further gene resequencing of this set of cases led to 
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the discovery of mutations in the progranulin gene from this region, which are responsible 
for many cases of FTDP-17.9   
In its natural state, MAPT works to stabilize microtubule formation and regulate 
transport along microtubules.13  Dysfunctional tau proteins can interrupt axonal transport by 
reducing the cell’s ability to control microtubule formation, ultimately leading to neuron 
dysfunction and death.8  Normally, the tau protein is located in axons, but in diseased cells it 
will relocate to the cell body and form insoluble hyperphosphorylized fibrillary inclusions.15  
This hyperphosphorylation of tau may lead to a loss of microtubule affinity and a resistance 
to proteases, leading to aggregation.2  Six major isoforms are produced in the adult human 
brain through the alternative splicing of exons 2, 3, and 10.13  The 6 isoforms can be divided 
into 2 groups, depending on the number of microtubule binding domains.  Alternative 
splicing of exon 10 will lead to four repeat (4R) binding domains or three repeat (3R) binding 
domains.13  The number of binding domains affects the binding of tau to tubulin; 4R tau will 
bind stronger and assemble more efficiently than 3R tau.13  A reduction in binding efficiency 
may increase the amount of unbound tau in the neuron leading to aggregation, although 
increased binding may have an equally damaging effect.13  An accumulation of unbound tau 
may result if any isoform fails to function, creating insoluble inclusions.8  Inclusions found in 
affected individuals may contain all 6 isoforms in equal amounts or different ratios of 
selected isoforms.  Many mutations disrupt the splicing of exon 10, leading to unequal ratios 
of 3R and 4R ratios.  Tau deposits in PSP and CBD are predominantly 4R, where deposits in 
FTD contain equal levels of 4R and 3R.10,15   
The region containing the MAPT gene has been shown to be genetically complex due 
to an inversion commonly found in Caucasian populations.  There are three highly 
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homologous low copy repeats (LCRs) that flank the region.3  The two LCRs telomeric of 
MAPT, LCRs B, and C are inverted relative to the centromeric LCR A.3  LCR A and LCR B 
flank the MAPT haplotype, suggesting that the inversion was caused by non-allelic 
homologous recombination. 3  Figure 3.1 shows the structure of MAPT in relation to these 
LCRs.  Extensive genotyping across the interval identified two haplotypes in almost 
complete disequilibrium.14  These haplotypes are commonly referred to as the H1 and H2 
haplotypes.  Recombination within the inverted segment between carriers of the H1 and H2 
haplotype would result in a Robertsonian translocation.  The high degree of disequilibrium in 
this region suggests that recombination has been suppressed or that there was a selection 
against recombinant chromosomes prior to the inversion becoming established in the 
Caucasian population.1  A study on the expression of tau in Alzheimer patients found that 
one variant of the H1 haplotype led to an increase in overall tau levels and specifically an 
increase in 4R tau creating an imbalance of isoforms.7  Similar changes in expression could 
be found in these diseases. 
There is a locus in or near the MAPT gene that clearly affects susceptibility to PSP 
and CBD. Conrad et al established that common variations in the MAPT gene affect 
susceptibility to PSP.2  They reported that the a0 allele of a dinucleotide repeat marker 
located in intron 9 of MAPT is observed in 57% of control chromosomes compared to 95.5% 
of PSP cases.2  The a0 allele was also shown to be overrepresented in CBD chromosomes.4  
Other tauopathies have a less certain association with MAPT region polymorphisms.2  The a0 
allele is not believed to be biologically relevant to the disease process, but is instead in 
linkage disequilibrium with some other polymorphism.2  The a0 allele is inherited with the 
H1 haplotype, so it is not surprising that the H1 haplotype is also overrepresented in PSP 
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cases.1  It is uncertain whether the increased risk for PSP and CBD is associated with a 
specific common variation of the haplotype or a rare mutation that is found on same 
chromosomes with the H1 haplotype.2   
Despite the varied clinical features that are used to categorize the different diseases, 
there is quite a bit of overlap, suggesting that there could be a shared underlying biochemical 
abnormality resulting from the altered expression of tau.4  In order to explore this possibility, 
we performed a high density association scan looking for markers that may confer 
susceptibility to several different tauopathies.  In this report, we focus on the markers 
contained in the region including and surrounding tau.  Using our data, and genotypes 
imputed using Hapmap, it was shown that a significant association exists across the entire 
inverted interval on chromosome 17 for PSP and CBD cases. 
 
3.3 Methods 
3.3.1 Sample Collection and preparation 
The samples included in the study were collected by the Memory and Aging Center at 
UCSF or by KCW.  Cases of PSP, CBD, FTD, and FTD with amyotrophy were collected 
from an unrelated Caucasian population.  Cases of FTD met Neary criteria and PSP met 
Litvan criteria.  While all cases were clinically confirmed, only 46 had pathological 
confirmation of disease.  None of the cases have known tau or progranulin mutations.  
Unaffected individuals from the same population were used as controls.  DNA was isolated 
from whole blood using the Puregene kit (Gentra Systems).  The number of patients used for 
each diagnosis in this study can be found in Table 3.1.  The number of cases per gender can 
be found in Table 3.2.  The average age was 73 for controls and 67 for cases with an average 
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age of onset of 60 years.  All subjects participated with informed consent procedures 
approved by the UCSF and UNC Human Subjects Institutional Review Boards. 
 
3.3.2 Genotyping 
Genotyping was performed using the GeneChip 500K Affymetrix SNP arrays using 
the protocol provided by Affymetrix.  The BRLMM algorithm was used to make genotyping 
calls.  Acceptable genotypes had confidence scores less than 0.5.  Any call that did not meet 
this threshold was removed from further analysis.   
 
3.3.3 Analysis 
The genotypes of cases versus controls were compared using a Fisher exact test to 
determine whether the allele frequency in the cases was significantly different from the 
controls.  Markers that were considered to be out of Hardy Weinberg Equilibrium were 
excluded from analysis.  There was no population stratification detected when tested with 
Eigenstrat.11  Genotype calls made by the BRLMM algorithm were used to infer the rest of 
the known Hapmap markers in the area based on correlation using the program Impute from 
the Chiamo suite.6  Imputed genotypes were considered acceptable with a posterior 
probability greater than 0.8, and markers were included in association tests if the call rate 
was greater than 80%. 
 
3.4 Results 
Genome wide, the average sample call rate was 95% and the average single 
nucleotide polymorphism (SNP) call rate was 92% on the Affymetrix 500K platform.  Less 
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than 1% of SNPs were out of Hardy Weinberg equilibrium and 1.5% of SNPs were 
monomorphic. 
From the 326 SNPs typed in the MAPT region ranging from approximately 40.4 Mb 
to 42.5 Mb on chromosome 17, we attempted to impute an additional 4,845 HapMap SNPs.  
After eliminating imputed polymorphisms with a posterior probability lower than 0.8, 1,477 
SNPs remained.  Of these, 60 SNPs were monomorphic and 68 were not in Hardy Weinberg 
equilibrium.  Any marker with a sample call rate less than 80% was removed.  Genotypes for 
1,169 genotyped and imputed SNPs were used to explore the region near the MAPT gene for 
allelic association with PSP, CBD, FTD, and FTD with amyotrophy. 
Figure 3.2a shows a plot of the probability that the cases and controls have equivalent 
genotype frequencies for each of the typed or imputed SNPs that met inclusion criteria for 
each of the disease classification models tested.  All of the significant associations observed 
are within the boundaries of the chromosomal inversion that distinguish the H1 and H2 
haplotype.  While there are some clear exceptions, the majority of markers across the 
inversion for any given comparison fall within a constant range of probabilities across the 
interval.  The most striking associations observed are for PSP alone or combined with CBD 
versus controls across the entire region of the chromosomal inversion.  Rarely a marker from 
other comparisons will reach a nominally significant association, but these events are rare 
and not constant across the inverted interval.  Inspection of the raw allele specific 
hybridization intensity for these markers does not robustly distinguish between genotype 
clusters and are not considered to be significant associations.  The region where allelic 
association is detected clearly defines the inversion interval boundaries.  Figure 3.2b shows 
the genotypes for all samples across the region of interest in the following order:  control, 
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FTD, FTD with amyotrophy, CBD, and PSP.  Each row represents an individual and each 
column represents a marker.  Known genes are indicated as lines above the genotypes.  The 
samples were sorted based on diagnosis and haplotype similarity.  Two distinct haplotypes 
can be identified in this figure consistent with previous designation of the H1 and H2 
haplotype.   
Table 3.3 shows the counts for the three haplotype combinations (H1/H1, H1/H2, 
H2/H2) for each category of diagnosis.  Very few heterozygous haplotypes, and no 
homozygous H2 haplotypes, were seen in either PSP or CBD.  When compared to controls 
using a fisher exact test, only PSP and PSP/CBD were significantly different.  This confirms 
that the H1 haplotype is overrepresented in PSP and CBD cases when compared to controls, 
while both FTD and FTD with amyotrophy had H1 levels in the same proportion as controls 
as seen in Table 3.4 which gives the percentage of H1 and H2 haplotypes in each group.   
 
3.5 Discussion  
The association found in these tauopathies across this interval on chromosome 17 
further supports the theory that one or more susceptibility loci in this region is affecting 
susceptibility specifically to PSP and CBD.  Since the markers are highly correlated and the 
association is seen across the whole region, it is difficult to narrow down a disease causing 
variant or even a possible candidate gene.  However considering the pathology of these 
diseases and the involvement of tau mutations seen in familial forms, the MAPT gene 
represents the most likely cause driving the association.   
While all of the diseases in the current study are part of what is referred to as 
tauopathies, not all of the diseases were highly associated with this region.  The hypothesis 
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leading to this study was that similar diseases were caused by mutations in genes controlled 
by similar biochemical pathways.  So while the mutation causing any particular presentation 
of one of these diseases may be located in different genes, the pathological outcome is the 
same.  There were other significantly associated regions in our genome wide scan which may 
be affecting susceptibility to the diseases which were not as highly associated with the tau 
region.  There was no association seen between FTD samples and this region even though 
cases with FTD can have tau inclusions and mutations of the tau gene have been found in 
affected families.  The lack of association may be influenced by our small sample size and 
the heterogeneity of sporadic FTD.  Most cases of FTD do not have tau mutations or 
inclusion, but cases of PSP and CBD are almost always accompanied by tau inclusions. 
The odds ratio was calculated to determine the risk associated with a particular 
haplotype.  Controls have a 7 fold greater odds (95% confidence interval 2.08-25.36) of 
having an H2 haplotype, on either one or both chromosomes, compared to PSP and a 4 fold 
greater odds (95% confidence interval 1.16-15.10) when compared to CBD.  When CBD and 
PSP are considered together, the odds ratio is in the middle with a value of 5.7 (95% 
confidence interval 2.24-14.62).  This suggests that the H2 haplotype provides some 
protection from the PSP and CBD diseases.  This proposed protective allele is considered to 
be significant for PSP, CBD, and PSP+CBD since none of the confidence intervals go below 
1.   
Imputation filled in missing genotypes and genotypes for markers not included in the 
Affymetrix chip 500K sets.  This gave a fuller picture of the association in the region.  
Imputation methods are useful for association studies since they combine information from 
genotyped markers with existing datasets such as Hapmap.  Testing a larger number of 
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markers across the genome provides a finer grid for association.  However in an area of high 
linkage disequilibrium, as in the chromosome 17 inversion, the true disease causing variant 
cannot be distinguished from the surrounding markers even with the extra imputed 
genotypes.  Imputation added little to our association due to the strong LD in the region that 
was implicated. The regions flanking this inversion are much more thoroughly evaluated and 
there is little reason to investigate these flanking regions further.  Filtering the data for call 
rate and posterior probability removed noise and most false positives that were detected 
using unfiltered data.  The genotype calling software which used to impute genotypes 
resulted in more stringent and reliable genotyping calls.   
The results from this association study provides strong evidence that a susceptibility 
locus in the MAPT gene region is related to certain Pick Complex diseases, but the high 
degree of linkage disequilibrium in the region makes it difficult to draw conclusions about 
the exact location of the locus.  To our knowledge, previous studies have reported results 
from candidate gene studies focusing on the tau gene.  We instead looked at the entire region 
and found an association with the entire inversion region with no evidence that any part of 
the region is more important than any other.  The genotypes are constant across the inversion 
due to the high level of linkage disequilibrium, but outside of the inversion they become 
highly variable with no identifiable pattern.  This is also supported by the constant level of 
association that drops off at the boundaries of the inversion.  The inversion is likely a recent 
event since it is only found in Caucasian populations.  While a specific cause cannot be 
determined, something in the inversion is likely affecting expression of the tau gene and 
ultimately disease status.  The inversion, or more specifically the H2 haplotype, appears to 
offer some protection against PSP and CBD.   
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Figure 3.1 Tau Gene Region 
Figure 3.1 shows the structure of the Tau gene, indicating the locations of microtubule 
binging domains and flanking LCRs.   
 
 
Figure 3.2 Association and haplotypes across the interval  
a) Figure 3.2a shows a plot of the negative log of the p value from the comparisons between 
cases and controls.  Known genes are represented as lines at the top of the figure. 
b) Figure 3.2b shows the genotypes for all samples across the region of interest.  Each row 
corresponds to a sample.  The samples were sorted based on diagnosis and haplotype 
similarity.  Samples with mostly blue or major alleles have the H1 haplotype while samples 
with mostly yellow or minor alleles have the H2 haplotype.  Samples with mostly red or 
heterozygote alleles are H1/H2.  The figure was created using the NIEHS SNPs Visual 
Genotypes program.14 
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Figure 3.2 
Table 3.1 Number of Samples included per Diagnosis 
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Table 3.1 shows the number of samples genotyped for each diagnosis type. 
Diagnosis Count 
Control 98 
FTD 56 
PSP 36 
CBD 23 
ALS 18 
 
Table 3.2 Gender of Patients in Study 
Table 3.2 shows the breakdown of samples by gender 
 Male Female 
FTD 32 24 
PSP 20 16 
ALS 11 7 
CBD 9 14 
Control 42 56 
 
Table 3.3 Comparison of Haplotypes 
Table 3.3 shows the p value and odds ratio based on haplotype counts for each diagnosis. 
 H1/H1 H1/H2 H2/H2 p value Odds 
Ratio 
Confidence 
Interval 
Control 59 35 4    
PSP 33 3 0 0.0011 7.27 2.08-25.36 
CBD 19 3 0 0.061 4.19 1.16-15.10 
FTD 37 15 4 0.4617 1.29 0.65-2.55 
MND 11 6 1 1 1.04 0.37-2.91 
PSP+CBD 52 6 0 0.0002 5.73 2.24-14.62 
ALL 100 27 5 0.0311 2.07 1.17-3.64 
 
Table 3.4 Percentage of Haplotypes 
Table 3.4 shows the percentage of samples of each diagnosis with the H1 haplotype. 
 Control PSP CBD FTD MND PSP+CBD ALL 
H1 153 69 41 89 28 110 227 
H2 43 3 3 23 8 6 37 
total 196 72 44 112 36 116 264 
%H1 0.781 0.958 0.932 0.795 0.778 0.948 0.860 
  
 
Chapter 4 - The evaluation of Convergent Haplotype Association 
Tagging: a novel algorithm for haplotype phase inference 
 
4.1 Abstract 
Current approaches for the identification of genetic influences of complex disease 
typically focus on the effect of one genetic variant at a time.  Consecutive variants along a 
chromosome are inherited together as a haplotype and knowledge of this haplotype can be 
very beneficial to genetic analysis.  The statistical prediction of haplotype, referred to as 
haplotype phase inference, has proven difficult when applied to the ambiguous genotypes 
created by conventional genome-wide SNP genotyping methods. A new approach, 
Convergent Haplotype Association Tagging or CHAT, was created to search for subsets of a 
population that share a long haplotype and to phase haplotypes based on the identified 
sharing.  In order to test the performance of the haplotype phase inference capabilities of 
CHAT, comparisons were made with three publicly available haplotype phasing programs: 
ENT, HaploRec, and Beagle.  Performance comparisons were based on two calculations of 
accuracy: the single site error rate, which measures the percentage of heterozygous loci 
incorrectly phased according to the true sequence, and the switch accuracy, which measures 
the number of recombinations needed to regain the true sequence.  The programs were 
applied to simulated data generated to mimic world populations. CHAT made very accurate 
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haplotype predictions especially when applied to a sample set with a large number of 
individuals; however, due to the nature of the algorithm it is only able to improve the 
haplotype phase for regions with haplotype sharing.   
 
4.2 Background 
4.2.1 Haplotype-based association analysis 
Current approaches for the identification of genetic influences of complex disease 
typically focus on the effect of one genetic variant or marker at a time and assume each 
marker is independent.  Consecutive markers along a chromosome are actually inherited 
together and knowledge of this configuration can be very beneficial to genetic analysis.  The 
combination of alleles for nearby markers on a single chromosome is referred to as a 
haplotype.  In single marker association analysis, we assume that a genotyped marker will be 
able to represent the variation of an untyped, causal variant.  Unfortunately, many association 
studies are unsuccessful at identifying a reproducible causal variant.  Considering multiple 
genotyped markers improves the chance that the untyped variant can be captured, especially 
if the variant is rare in the sampled population due to selection or recent mutation.1 
Haplotype based association analysis seeks to find association between a trait and an 
ancestral haplotype harboring a variant that influences the trait.  Individuals with the trait 
affected by the same causal variant will have varying amounts of the ancestral haplotype 
containing that variant.  The intersection of these haplotypes can map the trait-causing 
variant to a smaller chromosomal region with greater certainty than by single marker 
analysis.  In this way, haplotypes can provide more information and improve the power to 
detect a variant associated with the trait.   
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Although knowledge of haplotypes is advantageous for genetic analysis of complex 
human disease, haplotype based analysis has been limited.  Current genotyping platforms 
used in genome-wide association studies provide only the genotype at each position, either 
heterozygous or homozygous for any particular allele, with no indication about the placement 
of each allele on a chromosome in relation to other genotyped markers.  For this type of data, 
the haplotype phase, or set of markers together on a chromosome, must be predicted after 
genotype assignments have been determined.  Haplotype phase inference refers to the 
identification of haplotypes in genotyped samples by determining which alleles are inherited 
together on a single chromosome.  Two copies of each marker are typically present in every 
diploid organism—one inherited from the maternal chromosome and one from the paternal 
chromosome.  Complete inherited parental chromosomes are broken up by recombination, so 
that the grand parental origin for a region will vary across the length of the chromosome.  In 
a small region, markers are less likely to be separated by recombination and more likely to be 
inherited together.  Given this correlation between nearby markers on a chromosome, 
referred to as linkage disequilibrium or LD, markers located closely together will more often 
be inherited as a single haplotype, while markers farther apart are more likely to be separated 
by recombination.   
 
4.2.2 Genetic approaches to haplotype phase inference 
Early genetic studies were family-based linkage analyses which considered the 
sharing of alleles between relatives often using sibling pairs or parent child trios.  Using 
family genotypes simplifies phase inference, but phase is ambiguous if all family members 
are heterozygous.  The recruitment of family members can be difficult, especially for late 
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onset diseases, and increases the genotyping costs.  With the transition to large scale case-
control association studies, the phase inference capabilities provided by genotypes of 
relatives have been lost.   
As an alternative to family based haplotype phase determination, a variety of 
molecular genotyping methods are available to determine phase by separating the 
chromosomes and genotyping each directly.  These include single-molecule dilution, long-
range allele specific PCR, diploid to haploid conversion, pyrosequencing, rolling circle 
amplification, etc.11,12  Compared to SNP genotyping, molecular haplotyping methods are 
expensive, low throughput, and often unreliable.11,12   
Both molecular genotyping and family based methods are unacceptable for haplotype 
phase inference of large case-control association studies.  Effective haplotype analysis 
requires a quick, reliable, and cost effective method to phase millions of ambiguous 
genotypes created by conventional genome-wide SNP genotyping methods for large groups 
of unrelated individuals. 
 
4.2.3 Statistical approaches to haplotype phase inference 
Early statistical based haplotype phase inference algorithms were created for a small 
number of markers and samples.  The earliest described algorithm for haplotype phase 
determination was a maximum parsimony approach by Clark.4  While Clark’s method is 
straight-forward and able to handle a potentially large number of markers, the algorithm 
depends on the identification of one completely unambiguous individual in the dataset.  As 
the number of markers increases, the likelihood of finding an individual with no more than 
one heterozygous genotype becomes vanishingly small.  More recently, the standard for 
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haplotype phase inference has been PHASE v2.013 which uses a Bayesian approach and fits 
model parameters based on Markov Chain Monte Carlo.  The algorithm uses an approximate 
coalescent prior probability assuming that haplotypes from the same population cluster 
together due to shared ancestry.  While the program can deal with larger sets of genotypes by 
focusing on short subsets, it is still not practical for dense SNP data and large sample sets 
typical for GWAS. 
Contemporary statistical algorithms have been developed to handle genome-wide 
association data.  The three programs chosen for comparison in the current study were ENT, 
HaploRec, and Beagle.   
ENT7 attempts to maximize the likelihood of phasing using a count-based estimation 
of haplotype frequencies.  It is capable of phasing long stretches of genotypes by using an 
overlapping window and batched implementation where a section of previously phased 
haplotypes is included in the model to aid in phasing the neighboring section of genotypes.  
The algorithm iteratively changes the phase of an unknown set of haplotypes until the 
calculation of entropy is minimized.   
HaploRec5 is a likelihood expectation maximization based method that considers the 
local regularities observed between haplotypes.  The expectation maximization, or EM, 
algorithm was first used for haplotype phasing by Exoffier and Slatkin.6  Population 
haplotype frequencies are initially estimated and iteratively updated to maximize the log-
likelihood function to estimate an updated set of genotype frequencies.  The frequencies are 
iteratively updated until the frequency converges.6  The overall probability of the haplotypes 
is derived from the probability of local fragments.  This method uses long variable fragment 
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sizes based on a fragment threshold and takes advantage of information contained in long 
maps.   
Beagle2 uses a localized haplotype cluster model to define a hidden Markov model to 
determine the most likely phased haplotype for each individual.  The haplotype is modeled as 
a string of sites with a finite number of states at each site, with an emission probability for 
any given state to transition to another state at the next site.1,2  The Viterbi algorithm is 
applied to the hidden Markov model to determine the single most likely phased haplotype.1  
The inclusion of localization avoids sampling irregularities across long regions leading to 
false correlation between distant markers.  Observed haplotypes are grouped into clusters 
depending on similarity allowing the model to adapt based on the data.   
While these algorithms vary on their accuracy and efficiency, they tend to perform 
poorly across recombination hotspots, meaning the localized haplotypes may be phased 
correctly when considered individually, but placed on the wrong chromosome strand when 
combined with haplotypes from flanking regions. 
 
4.2.4 CHAT: A new option for haplotype phase inference 
A new algorithm for haplotype based analysis, known as Convergent Haplotype 
Association Tagging or CHAT, is currently under development in the Wilhelmsen lab.  This 
algorithm searches for subsets of a population that have inherited a long shared haplotype, a 
CHAT, harboring a mutation from a common ancestor.  Figure 4.1 illustrates the inheritance 
of an ancestral haplotype harboring a disease-causing mutation.  As described earlier, 
identifying haplotypes implicitly can be difficult given the phase unknown genotype data 
provided from genome-wide association data.  As an alternative, a pair-wise comparison of 
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samples determines whether it is possible for each pair to share a haplotype at any given 
location.  The only case when sharing is not possible is when two individuals are 
homozygous for the alternative alleles of a SNP (AA vs BB).  The assumed haplotype in the 
region of sharing can be determined from the consensus haplotype of the individuals 
identified.   
CHAT evaluates a pair-wise comparison of all subjects with genotype data for the 
potential for long shared haplotypes starting at each seed location.  The distribution of 
observed sharing is assumed to be the sum of a distribution due to what would be seen by 
chance (which can be modeled as a Gaussian distribution) and the distribution of sharing of 
the rare pairs of individuals that have a long shared haplotype.  CHAT models the combined 
distribution given the length of potential sharing and a prior probability of sharing that 
estimate the probability that the subjects share a long haplotype. 
The length of the shared haplotype and the allele frequencies of specific alleles found 
on the haplotype are used to calculate the Pi-SMOR statistic, a measurement of the likelihood 
that the haplotype is inherited identical by descent or from a common ancestor.  Pi-SMOR is 
the cumulative sum for markers in the putatively shared chromosome segment of the 
negative log of the single marker odds ratio of the probability of the observed genotypes 
assuming identity by descent of greater than 1 to the probability of the observed genotypes 
assuming identity by descent of zero.  This measure reflects the uniqueness and length of a 
putative long shared haplotype.  The Pi-SMOR statistic was developed to overcome the 
problem that an individual with a long string of heterozygous markers has the potential to 
share a haplotype with many other samples for the segment. 
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Using all the putative long shared haplotypes that individual X shares with others, a 
consensus haplotype for individual X can be predicted. CHAT uses the putative long shared 
haplotypes that involve subject X with the largest PiSMOR statistic to set phase and allows 
data from additional putative long shared haplotypes to further resolve the phase as long as 
they are parsimonious with the previously phased haplotype. After phasing subject X and 
other samples that putatively share a haplotype with subject X, CHAT tests whether the 
solutions are consistent. We describe this as a transitive test. We have observed that the most 
common reason why the phase solution for subject X (and the other subjects that putatively 
share a haplotype with subject X) are incompatible is that one of the putative long shared 
haplotypes is a false positive. By iteratively phasing subjects, and performing a transitive test 
to remove presumed false positive putative long shared haplotypes, CHAT converges on the 
most parsimonious haplotypes across long shared haplotypes. CHAT has the capability to use 
local entropy minimization to infer the haplotype of remaining chromosome segments as 
nearly as efficiently as other commonly used phasing programs.  
The goal of the current study was to test the performance of CHAT on the haplotype 
phase inference of simulated data sets generated under a number of conditions and compare 
the performance to other haplotype phase inference programs in regards to the overall 
accuracy across the entire simulated region and the ability to minimize the localized 
haplotype effect.   
 
4.3 Methods 
4.3.1 Data Simulation 
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Fregene was used to simulate data with known haplotype phase.3,8 Fregene is a 
forward data simulator that generates sequence data for large populations under various 
conditions allowing for control over selection, population level changes, rates of mutation, 
and patterns of recombination.  The program tracks the sequence level changes of a 
population as mutations and recombination events arise through the creation of generations 
by simulated random mating.  Each new individual in a subsequent generation is created 
from two random sequences from the previous generation.   
The Population C dataset3 available from the Fregene website was chosen for analysis 
as it is more likely to achieve the high level of complexity found in a real dataset than any 
user generated dataset.  It was created with the intention of mimicking the patterns of genetic 
variation found in major human populations worldwide.3  A series of events were simulated 
to mimic the creation of African, European, and Asian populations.  (It should be noted that 
while these populations are referred to as “African,” “European,” or “Asian,” they do not 
represent the true population of the same name and could not be considered as a subset of 
that population.)  The Fregene website provides a set of simulations assuming neutral 
selection and another that includes selection.  Throughout the simulations, mutations were 
allowed to occur at a rate of 1.5x10-8 and recombination at a rate of 1.1x10-8. 
To simulate the creation of current world population, a number of steps were taken to 
mimic the history of actual human populations.  Figure 4.2 summarizes the data simulation.  
To begin, a population of 25K sequences is created in “Africa” and allowed to evolve for 
125K generations.  The African population further expands to 48K sequences and continues 
for another 17K generations.  From this set, 4K sequences leave Africa, termed the Out Of 
Africa population, and the remaining bottleneck to 380 sequences.  The African and Out of 
  72
Africa populations expand to 48K and 15.4K respectively and evolve for 3.5K generations.  
The Out of Africa population experiences a bottleneck to 1.3K sequences and splits into a 
“European” population of 320 sequences and an “Asian” population of 1K sequences.  The 
European and Asian populations expand to 15.4K sequences and evolve for 2K generations.  
During this time, migration is allowed to occur at a rate of 0.8x10-5 between the Asian and 
African populations and 3.2x10-5 between the European and African populations.  Finally 
each population evolves independently until each reaches 50K sequences.   
 
4.3.2 Data Sampling and Dataset Creation 
Sample,3 a companion program for Fregene, was used to sample from the simulated 
sequence-level population data to obtain genotype data.  For simplicity of comparison, 
sampling was performed on the African neutral selection population, the European neutral 
selection population, and the European positive selection population.  African and European 
populations with neutral selection were chosen to compare differences in performance related 
to the level of linkage disequilibrium in a population.  The European populations with neutral 
or positive selection were chosen to compare the effect of selection.  The standard sampled 
population size was 1000 individuals.  An additional dataset was created with 2000 
individuals from the European positive selection set to understand the effect of sample size.  
Ultimately four sets were generated for comparison: African with neutral selection, European 
with neutral selection, European with positive selection, and European with positive selection 
and a large sample size. 
 
4.3.3 Haplotype Phase Inference 
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Fregene generated genotype data was transformed into formats appropriate for each 
haplotype phase inference algorithm.  ENT version 1.0.2 was applied to each dataset using 
default operating conditions suggested for optimal use, where free and locked window sizes 
are automatically selected and batching is included.  Beagle version 3.1 was applied to each 
dataset using default operating conditions.  Under these conditions, 4 haplotype pairs were 
sampled for each subject during each iteration and 10 iterations were applied per run.  When 
HaploRec was applied to each dataset, a window size of 1000 markers and an overlap of 250 
markers was chosen so that the program could complete the analysis given the available 
computational resources.  Other operating conditions were default, where a variable order 
Markov Model with smoothed probabilities was used, iterations continued until the 
likelihood was unchanged, and a sequential pruning strategy was applied that builds 
haplotypes along the chromosome one marker at a time.  CHAT was applied to the datasets 
under standard operating conditions.    The operating conditions chosen for each program 
may not be the optimal conditions for accuracy, but default conditions were chosen in each 
case to understand the baseline accuracy levels. 
 
4.3.4 Haplotype Phase Comparisons 
To understand the accuracy of haplotype phase inference provided by each program, 
the experimentally phased haplotypes were compared to the real haplotype provided from 
Fregene.  For performance comparisons, three measurements of accuracy were calculated.  
First, the single site error rate, described by Stephens and Donnelly,14 provided a 
measurement of how well each program could recreate the whole phased chromosome.  The 
single site error rate was calculated as the number of incorrectly placed alleles divided by 
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total number of heterozygous markers averaged across samples.  Second, the switch error 
rate was calculated as the number of contiguous heterozygous sites correctly phased or the 
number of switches needed to regain the original chromosome.  The switch error is able to 
show how well each program performs across sites of recombination.  A related 
measurement described by Lin9 is the switch accuracy calculated as (het-1-sw)/(het-1).  Like 
the switch error used in the present study, the switch accuracy represents the number of 
switches needed between neighboring pairs of heterozygous sites to regain the true haplotype 
sequence and is roughly equivalent to 1-switch error.   
 
4.4 Results 
The amount of change for each average error comparison between sample sets is 
shown in table 4.1 which displays the fold change for each comparison.  Statistically 
significant changes are indicated in bold and were determined through a t test comparing the 
error measurements generated by each dataset.   
 
4.4.1 Single Site Error Rate 
With regards to single site error rate, CHAT performed better overall compared to all 
other programs.  Beagle performed better compared to ENT and HaploRec which both had 
single site error rate near 50%, not much better than chance.  There was wide variation in the 
individual sample single site error rates for Beagle and CHAT.  ENT and HaploRec were 
more precise in their inaccuracy.  Figure 4.3 shows a histogram of the average single site 
error rate for each program. 
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Single site error rates ranged between 0.16-0.19.  Compared to the other haplotype 
phase inference programs, CHAT had a consistently lower single site error rate.  CHAT 
demonstrated a significantly lower single site error rate with the African sample compared to 
the European sample and performed better with a dataset with more samples.   
When considering program specific analysis, Beagle performed better than ENT and 
HaploRec with regards to single site error rate with average values ranging from 0.25-0.30.  
When considering the different datasets, the single site error rate was better for the African 
sample compared to the European sample, better with neutral selection than with positive 
selection, and better with a larger number of samples.  While ENT performed poorly overall 
in regards to the single site error rate with average values ranging from 0.46-0.47.  HaploRec 
performed slightly better than ENT with single site error rates ranging from 0.40-0.43.  The 
single site error rate was lower for the European sample compared to the African sample and 
lower with neutral selection than with positive selection.   
 
4.4.2 Switch Error Rate 
When considering the switch error rate, Beagle performed better than all other 
programs with average rates between 0.01-0.03.  Again, ENT had the highest switch error 
rates ranging between 0.25-0.36.  CHAT (0.06-0.12) and HaploRec (0.08-0.18) had similar 
rates, with CHAT performing slightly better.  Figure 4.4 shows a histogram of the average 
switch error rate for each program. 
All four programs showed similar trends when considering individual dataset 
comparisons.  With one exception, all programs had a significantly lower switch error for the 
African sample compared to the European sample, significantly lower with neutral selection 
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than with positive selection, and significantly lower with a larger dataset.  The one exception 
pertains to ENT which had a lower switch error rate for the European sample compared to 
the African sample.   
 
4.5 Discussion 
CHAT displayed a higher level of accuracy when compared to all other haplotype 
phase inference programs with regards to single site error rate.  However when considering 
switch error, of which CHAT was predicted to perform better, CHAT was able to outperform 
both ENT and HaploRec.  An increase in sample size consistently showed a significant 
improvement in the performance of all haplotype phasing programs, although the change was 
small for ENT and HaploRec.  A larger sample size provides a more complete sampling of 
the overall population and as a result improves the representation of rare haplotypes.  
Specifically for CHAT, a larger dataset increases the enrichment of sharing between 
individuals.  It is notable that in the large dataset nearly 30% of samples had a perfectly 
predicted haplotype phase configuration for the markers that were chosen for inclusion.  
Although the markers included in the phase determination was limited, an insurmountable 
number of individuals were phased for these markers with absolute accuracy.   
CHAT was able to have a high degree of accuracy when phasing because it was 
selective when choosing markers to include in the finished haplotype phase configuration.  
The publicly available haplotype phase inference programs determine haplotype phase for all 
markers entered into the program; however, CHAT does not attempt to determine the 
haplotype phase for all of the markers.  This is not surprising since CHAT was set up to 
determine phase only for markers covered by the shared haplotypes.  For the African sample 
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an average of 39% of markers were phased per sample, for the European sample with neutral 
selection 35.4%, for the European sample with positive selection 18.2%, and for the larger 
European sample 18.6%.   
Figure 4.5 shows the number of samples for each marker for which phased haplotype 
data was successfully generated by CHAT.  For the first 100 kb and the last 50 kb, phase was 
determined for around a hundred individuals.  Phase inference may be difficult for these 
regions because there is less overlap at the beginning and end of the sequence.  In the middle, 
most markers reach the upper limit of phased individuals with other markers scattered 
between phasing for 900 to 650 individuals.  Around 900 kb, there is a reduction in coverage 
as the number of successfully phased individuals drops to a range between 850 and 550 
individuals.  The genomic region covered by this reduction has a lower marker density which 
is likely influencing the drop in coverage.  This graph reveals that marker coverage is poor in 
regions of low marker density and at either end of the chromosome. 
As shown by the graph, the maximum number of phase determined individuals never 
reaches the maximum of 1000.  For the datasets with neutral selection, phase was determined 
for all samples for at least some of the markers.  For the datasets with positive selection, 
CHAT provided phased haplotypes for 90% of the samples: 89% for the European sample 
with positive selection and 92% for the larger European sample with positive selection.   
It was postulated that markers left unphased by CHAT were likely rare in the 
population and not contained in the common haplotypes easily identified as shared between 
individuals.  To improve the coverage of CHAT, an additional filter was applied to the 
dataset with the larger sample size to remove markers with a minor allele frequency (MAF) 
less than 5%.  A marker with a low minor allele frequency could be a recent mutation or 
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simply not represented well in the subset of the population sampled from the original, larger 
population.  In a real dataset, markers with low minor allele frequencies could also be due to 
genotyping error.  Regardless of the cause, exclusion of these rare markers can reduce the 
specificity required for the identification of shared haplotypes by reducing the rare 
haplotypes represented in the sample and allowing more individuals to be identified with a 
common haplotype.  The MAF filter greatly improved coverage and moderately improved 
phasing accuracy.  While 8% of samples were completely unphased when considering the 
full range of MAF, only 1.5% of samples remained unphased after the application of the 
MAF filter.  The average percentage of phased markers per individual also improved after 
the application of a MAF filter.  When applied to the complete dataset, an average of 81.4% 
of markers per sample were unphased.  After the MAF filter, an average of 60.5% of markers 
per sample were unphased.  This indicates that nearly a quarter of the original unphased 
genotypes had low minor allele frequencies meaning that they were rare in the population 
and likely not included in the haplotypes shared between individuals in the population.  The 
removal of markers with low MAF improved both the single site error rate and switch error 
by 1.3 fold.  However with regards to both measures, the improvement did not change the 
performance rankings of CHAT in relation to the other phasing programs.   
When comparing the performance on the various datasets within programs, there was 
improved accuracy for the African dataset compared to the European as well as for the 
neutral and compared to positive selection seen nearly consistently across haplotype phasing 
programs.  Haplotype phase inference should be more difficult in an African population 
compared to European since there should be greater diversity and more complex, shorter 
regions of linkage disequilibrium.  But this also results in a higher number of polymorphic 
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sites and thus a denser genetic map than the younger European population.  Likewise, 
positive selection will lead to less variation in haplotypes present in a population, but more 
polymorphic sites can develop under neutral selection.  This improved accuracy is likely 
driven by the density of markers found in each dataset.  It is logical to assume that a denser 
set of markers will provide a more complete picture of haplotype diversity and better 
frequency predictions leading to increased accuracy overall.   
The main goal of this study was to understand the accuracy of the haplotype phasing 
capabilities of a novel algorithm Convergent Haplotype Association Tagging, or CHAT.  
CHAT is unique compared to other haplotype phase inference programs because it restricts 
the search space of possible haplotype configurations by identifying haplotypes shared in a 
population that were inherited from a common ancestor.  When considering single site error 
rate, or how many markers were placed together on the same chromosome, CHAT 
consistently outperformed other phasing programs applied to the same data.  For switch 
error, or how flanking segments of the chromosome are placed, CHAT performed better  
when compared to ENT for the African set and the large sample set.   
Clearly the strength of CHAT lies in the ability to accurately predict the haplotype 
phase in regions covering long shared haplotypes for datasets with a large number of 
samples.  CHAT is very accurate with regards to single site error rate and moderately 
accurate concerning switch error on the markers that it does choose to phase.  To improve 
coverage, it is important to filter markers with low minor allele frequencies and to maximize 
the number of samples.  It is probable that coverage will improve with larger sample sizes 
given the trends comparing 1000 and 2000 samples; however, more complete coverage will 
likely come from reduced stringency in sharing or through an alternative method that can be 
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applied to fill in the unphased gaps.  While the current implementation of CHAT is unable to 
meet the complete coverage provided by current haplotype phase inference algorithms, it is 
possible to apply the entropy minimization technique implemented in ENT to determine 
phase for the markers left out by CHAT analysis.  It is likely that the high accuracy phasing 
across shared haplotypes provided by CHAT combined with the moderate accuracy provided 
by entropy minimization would provide both high accuracy predictions and better coverage. 
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Table 4.1 Fold change between comparisons 
 
The amount of difference between comparisons.  Values less than one indicate the first set 
had lower error rates, while values greater than one indicate the second had lower error rates. 
Haplo Haplo
Rec Rec
African vs 
European 0.95 1.02 1.07 0.9 0.79 1.04 0.86 0.69
neutral vs positive 0.91 1 0.94 0.98 0.38 0.71 0.5 0.73
sample size 
small vs large 1.22 1 1 1.17 1.82 1.01 1.04 1.23
Compared to 
CHAT
African 1.54 2.87 2.61 -- 0.17 4.27 1.25 --
European neutral 1.45 2.53 2.18 -- 0.15 2.85 1.01 --
European positive 1.57 2.48 2.28 -- 0.28 2.93 1.47 --
large sample 1.5 2.92 2.68 -- 0.19 3.58 1.75 --
Single Site Error Rate Switch Error
Beagle ENT CHAT Beagle ENT CHAT
 
  
Table 4.2 Significance Testing 
 
Provides the p values, as calculated through a student t test, used to determine significance in 
the comparisons between programs as seen in table 4.1. 
Haplo Haplo
Rec Rec
African vs 
European 4.32E-02 1.15E-18 6.21E-29 7.25E-03 3.31E-19 1.25E-20 1.26E-49 1.21E-20
neutral vs 
positive 3.89E-05 3.10E-01 1.13E-18 7.09E-01 1.19E-225 0.00E+00 0.00E+00 2.97E-15
sample 
size small 
vs large 3.81E-04 8.01E-01 6.11E-01 9.47E-16 3.44E-134 3.40E-03 5.93E-07 1.00E-21
Compared 
to CHAT
African 5.21E-35 0.00E+00 4.63E-299 -- 2.71E-123 0.00E+00 1.11E-15 --
European 
neutral 2.19E-32 0.00E+00 2.90E-232 -- 2.34E-170 0.00E+00 6.22E-01 --
European 
positive 5.26E-49 7.79E-259 2.60E-218 -- 1.65E-100 0.00E+00 8.98E-49 --
large 
sample 1.10E-97 0.00E+00 0.00E+00 -- 1.55E-131 0.00E+00 3.93E-246 --
CHAT
Single Site Error Rate Switch Error
Beagle ENT CHAT Beagle ENT
 
  84
Figure 4.1 Inheritance of Ancestral Haplotype 
 
Illustrates the inheritance of an ancestral haplotype harboring a mutation after several 
generations.  The initial chromosome represents the ancestral chromosome containing a trait-
causing mutation.  After several generations, individuals that have inherited the mutation also 
contain some amount of ancestral haplotype surrounding the mutation. 
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Figure 4.2 Data Simulation 
 
Diagram of Fregene generated data simulation.  A population of 25K sequences is created in 
“Africa” and allowed to evolve for 125K generations.  The African population further 
expands to 48K sequences and continues for another 17K generations.  From this set, 4K 
sequences leave Africa, termed the Out Of Africa population, and the remaining bottleneck 
to 380 sequences.  The African and Out of Africa populations expand to 48K and 15.4K 
respectively and evolve for 3.5K generations.  The Out of Africa population experiences a 
bottleneck to 1.3K sequences and splits into a “European” population of 320 sequences and 
an “Asian” population of 1K sequences.  The European and Asian populations expand to 
15.4K sequences and evolve for 2K generations.  During this time, migration is allowed to 
occur at a rate of 0.8x10-5 between the Asian and African populations and 3.2x10-5 between 
the European and African populations.  Finally each population evolves independently until 
each reaches 50K sequences.   
 
African 
European 
Asian 
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Figure 4.3 Single Site Error Rate 
 
Average single site error rates for the tested datasets for each haplotype phase inference 
algorithm.  Error bars represent the standard error of the measurement. 
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Figure 4.4 Switch Error Rate 
 
Average switch error rates for the tested datasets for each haplotype phase inference 
algorithm.  Error bars represent the standard error of the measurement. 
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Figure 4.5 Coverage 
 
Number of samples for which phase was predicted through CHAT for any given position. 
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Chapter 5 – Conclusions, Limitations, and Future Directions 
 
The fifth and final chapter of this dissertation will review the conclusions from each 
project.  Also included is a discussion of some of the major limitations encountered in the 
study of complex disease and how each relates to the current projects.  At the end, future 
directions for each project will be suggested as well as some predictions on the future of the 
genetics of complex human disease as a whole. 
 
5.1 Project Specific Conclusions 
5.1.1 The investigation of CYP2E1 with the level of response to alcohol 
Combined linkage and association analysis of the gene CYP2E1 was able to reinforce 
the implication that this gene, known for its metabolism of ethanol, affects the level of 
response to alcohol.  A genome wide linkage scan of sibling pairs with an alcoholic parent 
originally suggested the involvement of CYP2E1.  Variance component linkage analysis with 
the inclusion of a number of SNPs located in CYP2E1 confirmed the suspected linkage 
between this region at the end of chromosome 10 and the level of response to alcohol.  The 
reduced evidence for linkage after the addition of sibling pairs was attributable to a single 
family with unreliable phenotype measurements.  A number of SNPs genotyped from 
CYP2E1 were found to be associated with the level of response to alcohol through a mixed 
model regression, but copy number was not found to be associated.  So either the level of 
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response to alcohol is not affected by carrying multiple copies of the risk allele, or 
individuals with copy number changes did not carry the minor allele due to a low minor 
allele frequency (MAF = 0.056).  Testing for linkage while simultaneously modeling 
association allows for the confirmation of a causal variant or a variant in complete LD with a 
causal variant.  However tests showed that the most associated SNP could not be 
conclusively ascribed as a causal variant.   
It is likely that there are multiple causal variants in CYP2E1 in different families 
affecting the level of response to alcohol or that the single causal variant was not included in 
the SNPs chosen for genotyping in the gene.  If the latter is true, it is likely that the causal 
variant is upstream of the most associated SNP due to the trend in LOD score reduction.  The 
LOD score was reduced the most by the SNP that showed the best evidence for association, 
and the amount of reduction decreased for markers downstream on the chromosome.  The 
most associated SNP is located upstream from CYP2E1, so this unidentified causal variant 
could be located even farther upstream and have some kind of regulatory effect on the gene.  
Although a causal variant could not be identified, evidence from linkage, association, and 
knowledge of biological pathways indicate that changes in or near CYP2E1 regulate the 
activity or expression of this gene, thus affecting how the brain perceives alcohol leading to 
differences in the response to alcohol. 
 
5.1.2 The association of the MAPT region with Pick’s complex diseases 
A genome-wide association was performed on four different sub-types of Pick’s 
disease.  While a very large number of SNPs were found to be associated with different 
diseases, the results reported focus on the inverted region on chromosome 17 surrounding the 
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gene Microtubule Associated Protein Tau, or MAPT.  The association of this region with 
Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) supports 
previously reported associations of this gene with these diseases.  PSP and CBD most 
commonly include aggregates of tau, the protein product of MAPT.  The study was also able 
to replicate the overrepresentation of the H1 haplotype in this region in PSP and CBD.  
Either the H1 haplotype contains causal variants increasing risk, or the alternative H2 
provides some protection from PSP and CBD but not for FTD.  Due to the inversion 
surrounding the gene, it is difficult to narrow down an exact causal variant.   
 
5.1.3 The evaluation of a novel algorithm for haplotype phase inference 
A novel algorithm called CHAT was created to determine the haplotype phase of an 
unrelated set of individuals for genome-wide genotype data.  The current study aimed to 
understand the accuracy of haplotype phase inference on datasets simulated under different 
conditions as well as compared to publicly available haplotype phase inference programs.  
CHAT showed significant improvement regarding the single site error rate when compared to 
the other haplotype phase inference programs for all datasets.  Regarding switch error, 
CHAT was able to outperform ENT and HaploRec.  The coverage of haplotype phase 
inference performed by CHAT was very selective and directly dependent on the 
identification and overlap of shared haplotypes.  Although up to 30% of samples had 
haplotype phase configurations with perfect accuracy for the dataset with the larger number 
of samples, CHAT was not able to determine the phase for the complete length of the region 
for all samples.  The strength of CHAT lies in the ability to accurately predict the haplotype 
phase in regions covering long shared haplotypes for datasets with a large number of 
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samples.  CHAT is very accurate with regards to single site error rate and moderately 
accurate concerning switch error on the markers that it does choose to phase.  While the 
current implementation of CHAT is unable to meet the complete coverage provided by 
current haplotype phase inference algorithms, it is possible to apply the entropy minimization 
technique implemented in ENT to determine phase for the markers left out by CHAT 
analysis.  It is likely that the high accuracy phasing across shared haplotypes provided by 
CHAT combined with the moderate accuracy provided by entropy minimization would 
provide both high accuracy predictions and better coverage. 
 
5.2 Limitations and Challenges of Genetic Analysis 
The success of the studies presented here, as well as other studies of the genetics of 
complex human traits, is dependent on the ability to maximize the power to detect a genetic 
effect and to minimize the occurrence of false positive findings.  Many genome-wide 
association studies are not powered well enough to detect variants with large effects that can 
be distinguished from the noise of false positive associations.  While false positives can 
obscure the identification of true positives, overly strict exclusion criteria can be just as 
detrimental when true positives are eliminated along with the false positives.  What follows 
is a discussion of the many considerations to maximize power and achieve a balance between 
true and false positives.  Attempts to maximize power can be divided into six categories: 
sample considerations, phenotype considerations, the linkage disequilibrium or correlation 
between markers in a population, control for false positive results, replication of positive 
findings, and the genetic component of a phenotype or effect size. 
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5.2.1 Sample Considerations 
The power to detect a genetic influence for a trait increases with the inclusion of more 
samples.  The minimum number of samples needed to glean the most power from a genetic 
study and to minimize genotyping costs can be estimated based on features of the causal 
variant to be detected, including allele frequency, penetrance, and magnitude of effect, a 
measurement of the amount of risk provided by a variant. There is some uncertainty to this 
calculation because features of the unknown causal locus must be estimated as well.  But 
more often the sample size of a study is limited based on the availability of suitable affected 
individuals, as was the case with the Pick’s disease GWAS which focused on rare 
neurodegenerative diseases.   
There is a tendency to collect large sample sets and combine samples genotyped at 
multiple research centers in order to maximize the power to detect variants with smaller 
effects.  While this does increase the overall power, genotypes and phenotypes may not be 
consistent across research centers leading to biases resulting from the added heterogeneity.  
The CYP2E1 alcoholism project is one example where the intent to increase the power to 
detect an effect by the addition of extra samples was detrimental to the overall evidence for 
linkage.  Including more samples in a study will increase the chance for heterogeneity 
leading to the apparent association of regions unrelated to disease status thus increasing the 
chance for false positives or, as seen in the CYP2E1 project, obscuring the evidence for a 
genetic region that may actually affect disease—a false negative.  Heterogeneity can occur 
through incorrect sample definitions, either by poorly defined cases and controls or by 
differences in population ancestry.   
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Through the identification of appropriate cases and controls heterogeneity can be 
minimized.  For a qualitative trait of case/control, the status must be explicitly defined and 
easily differentiated.  The choice of phenotype will be discussed in detail later, but the 
phenotype should be easy to measure and reliably consistent.  Heterogeneity can be 
minimized if the cases share a specific subtype of a phenotype. Controls should come from 
the same population as the cases and be at risk for disease, but must be excluded from the 
disease or trait of interest.  In studies of substance abuse, like alcoholism, the controls must 
have had exposure to the addictive substance but not be addicted.  For a rare disease such as 
Pick’s complex it is unlikely that any control individual will be affected but it is important 
for age-related diseases like dementia be matched for age. The same is true for gender and 
any other variable unrelated to a genetic effect that could have an influence on the trait, like 
environmental exposures.   
Another consideration for reducing heterogeneity is the effect of population ancestry.  
Unlike linkage analysis, which controls for ancestral background internally through the 
inclusion of family members, association analysis is highly vulnerable to population 
stratification creating apparent correlations with variants unrelated to the trait.  Population 
stratification occurs when the ancestral composition differs between cases and control.  If the 
frequency of a specific allele is also different between the populations found in the sample, 
that allele could show a false association simply due to population effects.  The samples in 
the association study of Pick’s Disease were screened for European ancestry and population 
stratification was undetected by Eigenstat, a program that looks for stratification in GWAS 
data.  The effects of population stratification are minimized by restricting samples to a single 
continent of origin.  But stratification may even exist in a single continent if samples come 
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from different regional areas introducing more cryptic differences.  One way to reduce the 
effects of cryptic population stratification is to choose a homogeneous population isolate with 
a more recent common ancestor.  In a homogeneous population most mating occurs within 
the population and genetic variants affecting a trait are more likely to come from the same 
mutation and thus be located on the same haplotype.   
Genetic heterogeneity can also occur when multiple variant lead to the same 
phenotypic outcome.  Methods to minimize the heterogeneity created by the choice of 
phenotype will be discussed in the next section.   
 
5.2.2 Phenotype Considerations 
A search for regions of the genome that affects a trait will perform poorly if the 
phenotype is not well defined.  The CYP2E1 linkage study illustrates the importance of 
accurately reported phenotypes.  Skewed phenotype scores from one family were enough to 
introduce heterogeneity into the sample and obscure the genetic effect.  This addresses the 
importance of accurate phenotype measurements that can be reliably measured.  Complex 
human disease can be very heterogeneous; some diseases are defined by the occurrence of 
any number of symptoms.  For example, in the association analysis for Pick’s disease, each 
subtype of disease is defined by a number of clinical and pathological features, but the exact 
set of features can vary between individuals.  A trait needs to have a clear definition and be 
easily determined.  The different subtypes of Pick’s disease can be pathologically confirmed, 
but are often misdiagnosed at the clinical level.   
The choice of phenotype is also a concern for heterogeneity minimization.  Often the 
phenotype used in GWAS is a dichotomous classification of disease status.  Focusing instead 
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on a particular symptom, or endophenotype, of a disease can reduce heterogeneity and make 
a genetic cause easier to identify.  The CYP2E1 project focused on a quantitative trait, so 
there were no case/control determinations.  Instead, sample collection was restricted to 
individuals that had an alcoholic parent, thus increasing that individual’s own risk for 
alcoholism.  Focusing on individuals with a known high risk for alcoholism reduces the 
heterogeneity that could be encountered in a study of the risk for alcoholism in the general 
population.  Additionally, a specific measurement such as the level of response to alcohol is 
more likely to be affected by a similar genetic cause in different individuals compared to 
considering the broad definition of alcoholism.   
 
5.2.3 Linkage Disequilibrium Considerations 
The power to detect an untyped causal variant depends on the level of correlation 
between the genotyped markers and the causal variant.  The number of samples needed to 
detect an unmeasured causal marker is proportional to the level of linkage disequilibium, or 
r2 a measure of correlation, between the typed marker and the untyped causal marker.  The 
likelihood of measuring a marker in linkage disequilibrium with a trait causing locus can be 
improved by increasing the density of genotyped markers or by choosing a population with a 
recent common ancestor. In such a homogeneous population, the regions in linkage 
disequilibrium will be larger, so fewer markers will be required to cover all of the variation.  
Alternatively, the power to locate the exact genetic effect increases with the number of 
generations to a common ancestor due to the smaller size of region in linkage disequilibrium. 
The power of a genetic study increases with the inclusion of more distantly related 
pairs.  Association maximizes this power by comparing very distantly related individuals.  
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Compared to association based analysis, linkage analysis can map a trait to a very large 
region since linkage analysis is based on the inheritance of chromosomes from a very recent 
ancestor.  In the case of the sibling pairs used in the current study, that common ancestor 
would be the parents.  As a result, the comparison is made after only one meiosis and one 
chance for recombination leading to very large regions in LD.  This is illustrated in the 
linkage study to find regions that affect the level of response to alcohol where the linkage 
peak covered a large region.  While CYP2E1 provides the most logical evidence for 
involvement with our trait, there is not always such an obvious candidate gene in a region of 
linkage.  Association analysis provides a way to map a trait locus to a much finer region 
because the regions of LD are smaller.  Association analysis can be considered as an extreme 
version of linkage analysis.  It is often assumed in association that the samples collected from 
a common population are unrelated.  In reality, every individual in a population can be traced 
back to a common ancestor.  With many more generations, more recombination can occur, 
dividing the chromosomal region, or haplotype, from the common ancestor into much 
smaller pieces.  The length of haplotypes shared in a population from a common ancestor or 
the extent of linkage disequilibrium depends of the number of generations that have passed 
and the interrelatedness of the population.  An older population will have very short regions 
of LD while a younger, less heterogeneous population will have longer regions of LD.   
A densely mapped set of markers will increase the power to detect a genetic effect 
because it increases the probability that a genotyped marker is likely to have a sufficient 
correlation with the causal variant.  Regions of linkage disequilibrium in a linkage study are 
much larger requiring only a few markers to represent the genome.  In the genome-wide 
linkage scan to search for regions of the genome affecting the level of response to alcohol, 
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only 811 microsatellite markers were genotyped across the entire genome.  A much denser 
map is required for genome-wide association studies because the biallelic SNP contains less 
information and the regions of linkage disequilibrium are smaller.  A more densely 
genotyped map will increase the likelihood that a measured allele will be in linkage 
disequilibrium with the causal allele as it will be able to capture more of the common 
variation in the genome.  Similarly, the required number of markers to capture the variation 
in a population is dependent on the number of generations to the common ancestor.  An older 
population requires more markers to represent the larger number of LD regions.   
When the Pick’s Disease project was performed the Affymetrix genotyping chip only 
included 500 thousand markers, but current genotyping technology has allowed for the 
inclusion of up to a million markers.  Additionally, using the patterns of linkage 
disequilibrium among common SNPs captured by the International HapMap project,6 it is 
possible to increase the density of markers in a study by predicting, or imputing, markers not 
originally included on the genotyping chip.  Imputation was performed for the Pick’s disease 
project, but the prediction of untyped markers provided limited benefit because the region 
had nearly perfect correlation due to the high degree of linkage disequilibrium.   
 
5.2.4 Data Processing Considerations 
An overabundance of false positive results in a study will limit the power to identify 
an actual causal variant.  Careful study design through sample and phenotype guidelines, as 
described earlier, seeks to reduce false positives but is not enough to prevent all occurrences.  
Through improved genotype calling algorithms and extensive quality control, researchers 
aim to minimize the prevalence of false positive results.   
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The method of genotyping and subsequent data processing has a large influence on 
the success of a genetic study, especially for a genome-wide association study.  Because so 
many markers are being measured, even a small error rate will lead to a sizable excess of 
false positives.  It is very important that genotype calls be as accurate as possible.  In a 
genome-wide association study, genotype calls for each marker are made automatically using 
a genotype calling software.  Genotype calls for the Pick’s disease project were generated by 
the BRLMM algorithm which categorizes genotype based on the distance of each sample 
measured from the center of the three predicted clusters.1  The algorithm underlying 
BRLMM was explained in detail in chapter 1 of this dissertation.  At the time of the Pick’s 
disease study, BRLMM was the best available genotype calling method.  While the BRLMM 
algorithm was an improvement over previous genotype calling software, experience revealed 
that many markers are genotyped poorly.  The algorithm often misclassifies homozygous 
individuals as heterozygous, especially at low intensity levels or when clusters overlap.  
Experience has shown that systematic bias or batch effects in the genotyped samples will 
lead to poorly called genotypes.  Batch effects can occur due to any difference that could lead 
to biased genotype calls and improper associations.  These effects can come from differences 
in sample handling prior to genotyping, differences between plates of samples, or genotypes 
that were generated at different research centers.  After the determination of genotype, 
possible genotyping errors are removed through stringent quality control although experience 
has shown this is not always the case.   
Many quality control criteria were applied to the Pick’s disease dataset to reduce the 
chance for false positive associations.  The confidence score given by the genotype calling 
software for each genotype is used to distinguish acceptable genotypes from questionable 
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genotypes.  A call rate is calculated for each sample and each marker and individual samples 
or markers are removed if too many fail to pass the predetermined threshold rate.  
Additionally, a minor allele threshold is set to remove markers that are rare or monomorphic 
in the genotyped population.  Markers with low minor allele frequencies are especially 
susceptible to errors in genotyping and often lead to over-inflated measures of significance 
(extremely low p values).  Hardy Weinburg Equilibrium describes the allele frequencies 
expected from a stable population and is a calculation comparing the measured allele 
frequencies compared to the expected. Markers that do not meet criteria for Hardy Weinburg 
Equilibrium are likely to be a result of unreliable, biased genotype calls and are removed 
from analysis.  Often the best way to exclude poorly called markers is to visually inspect the 
probe intensity genotype plots and manually make genotype designations.  This can be easily 
performed with small scale Taqman genotyping efforts, but is nearly impossible when 
dealing with half a million markers at a genome-wide scale.   
 
5.2.5 Replication 
Even after stringent quality control and data processing, not all false positive results 
can be removed.  After any genome-wide scan for genetic variants, replication is required to 
confirm the positive results and increase the likelihood of the identification of biologically 
appropriate variants.  With so many statistical tests performed in an association analysis 
combined with the tendency for genomic errors and heterogeneity to cause biases, there is an 
increased potential for false positive findings, or associations that occur by chance, 
interspersed with true positive associations.  The most accepted correction for multiple 
testing is through the Bonferoni correction which divides alpha, the predetermined 
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significance threshold level for a single test or how often a test should reach significance by 
chance, by the number of independent tests performed.  This method is often described as 
overly conservative because SNP genotypes are not completely independent due to linkage 
disequilibrium.  Even so, the commonly accepted threshold for genome-wide significance is 
5x10-8 which corrects for one million SNPs.  The results from the Pick’s disease project did 
not reach genome-wide significance under this criterion, but many of the unreported 
associations did reach that level.  Considering so many different markers in this region 
surrounding MAPT independently show the same level of association and knowledge of the 
involvement of the gene with these diseases, it is certain that the association seen in the 
inversion across chromosome 17 is not a false positive. 
Many reported findings have been difficult to reproduce.  Either these studies are 
reporting false positives or the reproduction approach is not optimal.  For the best likelihood 
of replication, an independent sample should be taken from the same population, the same 
phenotypes should be measured, and the same markers should be genotyped.  A true 
reproduction will implicate the same SNP for the same allele in the same direction (meaning 
the same allele increases risk or provides protection).11  Often associations found in one 
population do not translate to other populations due to differences in ancestry and allele 
frequencies.5  When looking at variants from CYP2E1 that confer risk for alcohol related 
phenotypes, there is a lot of discrepancy between studies because they draw their samples 
from different populations with different allele frequencies and they focus on different 
phenotypes.  This is discussed in detail in Chapter 2.   
For a replication study, often the most significantly associated markers are chosen for 
genotyping in an alternate set of samples.  Errors in genotyping and biases in sample sets 
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more often lead to extremely significant associations, while the findings most likely to be 
robust across replication samples are less impressive.11  Often the markers with the best 
evidence for association, or most extreme p values, are chosen for replication. However, 
markers with less extreme association levels are more likely to replicate because they are less 
likely to be false positive results.  Experience from the Pick’s disease dataset and another 
GWAS not discussed in this dissertation has shown that these studies generate an 
overabundance of highly associated markers suggesting high false positive rates.  In these 
studies, markers with the most inflated association p values have very unlikely genotype 
counts and visual inspection of probe assay plots reveal that unreliable genotype call have 
been made. 
 
5.2.6 Effect Size (or the Genetic Component of a Trait) 
To be successful, a trait considered in a genetic study must have a large genetic 
component.  Obviously, it should be easier to ascribe a genetic cause to a trait caused by 
larger genetic effect.  The heritability of a trait refers proportion of the trait variance 
attributable to genetic effects and can be measured through twin studies by the concordance 
between dizygotic twins compared to monozygotic twins.  The level of response to alcohol 
was chosen as the phenotype for the CYP2E1 linkage study because evidence from previous 
studies showed that the trait was highly heritable and consistent in families where children of 
alcoholics had lower levels of response to alcohol than control individuals.  Additionally, the 
sibling relative risk for a trait or the disease risk for the sibling of an affected individual can 
be an indication of the feasibility of a study.  The sibling relative risk is calculated as the 
ratio between the sibling risk and the overall population risk.  A disease like FTD occurs in 
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families fairly often but has a vary small overall population risk, so the sibling relative risk is 
very large especially compared to other more common dementia related diseases like 
Alzheimer’s Disease.  Alternatively diseases like PSP and CBD occur sporadically thus have 
a vanishingly small sibling relative risk suggesting that a genetic cause for these diseases 
would be more difficult to identify. 
A large proportion of the heritability for most common, complex diseases has been 
left unexplained by identified genetic variants.5  Association studies were created under the 
assumption that common genetic variants are likely to cause common diseases and these 
common variants with smaller effect sizes could be detected in a population better than by 
linkage.  Association has increased power to detect variants that have a small effect of a trait 
than linkage.4  However, association analysis only has power to detect common causal 
variants that are in linkage disequilibrium with genotyped SNPs.  The detection of rare 
variants with larger effect sizes is technically feasible but would require unattainably high 
sample sizes.  Typically linkage analysis has greater power to detect rare variants with large 
effects for rare diseases since these traits tend to be found in multiple affected members of a 
family. But linkage is less successful than association analysis for complex traits influenced 
by multiple alleles in different genes contributing only a small amount to the overall risk.  
Haplotype analysis, especially as constructed through CHAT, provides a bridge between 
linkage and association since it can detect rare variants with small effects for a relatively rare 
trait.   
The Common Disease Common Variant, CDCV, hypothesis assumes that many 
common SNPs with small effect sizes and low penetrance could be detected to affect a 
common trait in a population if enough individuals were genotyped.3,7  Current genotyping 
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platforms are able to capture up to 80% of markers in the Caucasian population with minor 
allele frequencies greater than 0.05 but misses any markers with rarer allele frequencies.3  
The majority of markers found to be associated by GWAS have small effect sizes (1.1-1.5) 
and explain only a small proportion of the estimated heritability or underling genetic cause 
(5-10%).10,12  It is likely that the CDCV hypothesis is not entirely correct and the rest of the 
heritability may be explained by rare variants, copy number changes, and structural variation, 
as well as interactions between genes or between genes and environment.  To fully 
understand the genetic heritability of complex traits will require the investigation of these 
variants by deep sequencing or new genotyping platforms that can better capture rarer 
genetic changes.   
Variants able to explain more of the heritability with large effect sizes are expected to 
be rare and not well represented by common variation.  This is logical considering a mutation 
with a large effect on disease would likely be deleterious and be minimized in a population 
by selection since it would decrease reproductive fitness.2  Additionally stabilizing selection 
would seek to minimize the extremes of the trait caused by variants with larger effects.10  The 
best option for capturing rare variants with large effect sizes will be with sequencing either 
through targeted regions likely to harbor mutations or through a whole genome approach.  
The 1000 genomes project plans to sequence a thousand individuals with the hope of 
capturing rarer genetic variation with minor allele frequencies between 1-5%.3   
 
5.3 Project Specific Future Directions  
5.3.1 The investigation of CYP2E1 with the level of response to alcohol 
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It seems evident that sequence changes in or around CYP2E1 are affecting the 
expression or activity of this gene.  To understand how CYP2E1 is changed in response to 
chronic alcohol intake, the redox pair compound ratios could be measured in different mouse 
strains that respond to alcohol differently.  During CYP2E1 mediated metabolism, oxygen 
recruits an electron from hydrogen and NADPH resulting in NADP+.  The redox pair ratio 
compares the levels of NADP and NADPH in the brain, thus providing an indication of how 
much ethanol has been metabolized by CYP2E1.  Similar compounds can be measured for 
the alcohol dehydrogenase pathway allowing for the comparison of pathway activity.  To 
fully understand the sequence variants that affect the activity of CYP2E1, functional variants 
need to be identified either by sequencing or further SNP genotyping upstream of CYP2E1 to 
find regions that correlate with expression.   
A single causal variant may not be driving the evidence for linkage at the end of 
chromosome 10.  Since linkage analysis seeks to find regions of a chromosome that co-
segregate within a family, the specific variants can vary between families as long as they fall 
within the same region.  So there could be allelic heterogeneity among the families, where a 
small number of variants in the gene could be independently affecting the differences in the 
level of response to alcohol.  It is not fully understood what effect this would have on the 
identification of a causal variant as performed in this study.  It would be helpful to generate 
simulated datasets with multiple causal variants to understand how the measured genotypes 
affect the reduction of the LOD score when included as a covariate.   
A number of additional variables were available for the study of the level of response 
to alcohol.  During the alcohol challenge, blood alcohol levels and body sway were also 
measured.  It would be possible to look at the interaction of blood alcohol level and the level 
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of response to alcohol.  A linkage based study is family based and as a result is immune to 
population stratification.  Linkage analysis compares only the allele sharing and trait 
difference between family members, not across families. So even though the sample set was 
made up of different ethnicities, the genetic differences affecting the response to alcohol in 
the families were centralized to the region at the end of chromosome 10.  It would have been 
beneficial to include ethnicity as a covariate in association analysis to see if correcting for 
different genetic backgrounds increased our evidence for association.  The inclusion of 
families in the association analysis accounts for the within family variation and is likely 
protected from the effects of stratification.  It would also have been interesting to consider 
whether the alcoholic parent, mother or father, had any effect on the level of response to 
alcohol.   
The current dataset had phenotype data related to nicotine use, however this data was 
sparse since values were not reported for the entire sample.  Even so, it was shown that 
correcting for the average number of cigarettes smoked per day was able to increase the 
evidence for linkage.  Given the known interaction between alcoholism and nicotine use 
combined with the evidence of an enhanced effect during the metabolism of ethanol and 
nicotine by CYP2E1, it would be interesting to further investigate the effect of nicotine use 
on the level of response to alcohol and activity of CYP2E1 in a set of individuals who drink 
and smoke excessively.   
 
5.3.2 The association of the MAPT region with Pick’s complex diseases 
This association found between the inversions containing MAPT can be considered a 
true positive due to the well documented involvement of the gene with these diseases, 
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providing some level of plausibility for other positive associations found in the genome-wide 
study.  These other associations are not reported here because extensive data cleaning and 
replication is needed.  Replication is a necessary follow-up for any association study to 
minimize errors due to false positives and cryptic biases in a data set.  There were some 
compelling possibilities for positive association, with many that reach genome-wide 
significance, in genes involved with microtubules, endosomal trafficking, and angiogenesis.  
But they will not be discussed here in detail. 
It is likely that the H1 haplotype is harboring mutations in the MAPT gene leading to 
disease.  Imputation was used to predict the genotypes of markers not included in the study to 
provide a more complete picture of the common variation in the dataset. However, due to the 
high degree of linkage disequilibrium across the inversion, imputation provided no additional 
information about the association of this.  Sequencing is required to understand the rare 
variants that can distinguish different sub-haplotypes of H1 and H2.  The inversion is only 
present in the Caucasian population, so as an alternative, the study could be performed in a 
different population to provide a clearer picture of the region and possible causal variants 
although ascertainment of enough samples in an alternate population could be difficult due to 
the rarity of the disease.   
There are several known isoforms of tau and these isoforms are present in different 
ratios in different subtypes of Pick’s disease.  The main two types of isoforms depend on the 
alternative splicing of exon 10 resulting in three or four repeat binding domains.  Tau protein 
aggregates in PSP and CBD are predominantly made up of four repeat domains.  It would be 
informative to investigate possible splice variants in the gene leading to the overabundance 
of one type of isoform.   
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5.3.3 The evaluation of a novel algorithm for haplotype phase inference 
Analysis for this project was performed on a sequence of 1 Mb.  Compared to a 
standard full chromosome that would be provided by GWAS data, this is rather small.  To 
test data of that scale, it would be useful to apply the same performance criteria to the 10 Mb 
dataset provided through Fregene.  Parameters for computational job parsing would need to 
be optimized for the successful completion of analysis for the larger scale dataset, but it 
would be expected that CHAT would be able to predict the haplotype phase of a 10Mb 
dataset with better accuracy and coverage.   
CHAT was not created as a haplotype phasing algorithm and that is not its main 
purpose.  CHAT was created to identify long haplotypes shared by a subset of individuals 
with a certain trait in a population with the assumption that such a haplotype could harbor an 
ancestrally inherited causal mutation.  To test the performance of CHAT on the identification 
of trait-causing variants, simulated data can be generated by Fregene and Sample with 
case/control status and causal variants.   
 
5.4 The Future of the Genetics of Complex Human Disease 
Future genome-wide association studies need to be well planned and designed with 
more power to detect variants with small effects.  The most controllable way to increase 
power is through sample size.  Current studies include thousands of individuals and there is a 
trend for collaborations between large centers to combine genotypes into an even larger 
multi-center pool of data.  But care should be taken to ensure consistency between sites 
regarding both genotype and phenotype measurements.  As described earlier, systematic bias 
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in either type of measurement will lead to biased associations.  There is also a trend of 
focusing on subtypes of disease or intermediate symptoms, often referred to as 
endophenotypes.  This approach is helpful when there is complex heterogeneity in the 
disease definition and avoids the loss of information that results from the use of a disease 
endpoint as a phenotype.  This also allows for the comparison of symptoms that overlap 
across different diseases that could have similar biological causes. 
Many GWAS have identified variants that could be involved with diseases and some 
of these have been replicated.  When examining the association results from a variety of 
diseases, up to 80% of associated SNPs lie in intergenic or intronic regions with no obvious 
effect on expression.9,13  It is important now to determine the exact causal variants and 
understand how these causal variants create changes that lead to disease.  For the majority of 
identified variants, the effect that these variants have on expression leading to disease has not 
been obvious and detection of functional variants for most identified associations has been 
difficult.5,9  It is likely that the variants are tagging unknown causal variants which may be 
nearby or at some distance.  While linkage disequilibrium does decline with distance, it is 
complex and can span hundreds of kilobases.8  One SNP may tag a large number of markers 
that are interspersed among other, untagged SNPs.8  So extensive genotyping in a large 
region around associated markers is needed to identify probable causal SNPs.  The best 
option for considering all variants in a region would be deep sequencing. 
As mentioned briefly in the introduction, the field of the genetics of complex disease 
has been moving towards whole genome or whole exome sequencing to identify specific 
variants that increase risk for a disease or trait.  With next-generation sequencing technology, 
whole genome sequencing has become both time and cost effective.  Whole genome 
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sequencing addresses the problem of uncaptured rare variants seen in association studies.  It 
also bypasses the reliance on linkage disequilibrium between the genotyped variant and 
causal variant.  But the creation of massive genome-wide sequence level data presents a wide 
range of challenges regarding bioinformatics, data mining, and data management.  Just 
because the data can be created, does not mean we know what to do with it.  New 
applications must be created to efficiently sift through the data, identify variants, and make 
calculations.  Computational and statistical approaches that were appropriate for GWAS will 
likely not scale well for whole genome applications and more powerful computing resources 
will be needed.  Data management and storage will be a particular challenge.  There need to 
be ways to not only store the sequence data and compile results from many overlapping 
reads, but to retrieve that data and present it in a usable way.   
The immediate goal of the study of the genetics of complex human disease is to find 
genetic variants that increase risk for disease.  The long term goal is to apply this information 
to help treat or predict disease.  Genes containing risk variants can be targets for drug 
treatment which can alter expression to either up-regulate or down-regulate a gene as needed.  
Variants can be used to screen for individuals that are at risk for disease so that those 
individuals can modify their behavior or seek preventative help.  Genetic variants can be 
used to choose the best treatment for a disease—which drug or what dosage to minimize side 
effects.  But to be good predictors, genetic variants need to be easily measured, highly 
accurate, cost effective, and have an effect size large enough to actually confer enough risk to 
matter.  A genetic variant with an odds ratio of 1.1 will not increase an individual’s risk for 
disease much compared to the general public risk level.  A variant would also need to be 
relatively common in the general population, or it would be rarely seen and not practical for 
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clinical use.  A better option may be to use multiple genetic variants together as a biomarker 
to predict whether an individual will develop that disease based on their set of combined risk 
alleles.   
 
5.5 Final Thoughts 
The purpose of this dissertation was to apply various statistical and computational 
techniques to aid in the understanding of the genetics of complex human disease and the 
assessment of genome-wide datasets.  The presented projects demonstrate that even though 
regions of the genome that increase risk for a trait can be readily discovered the identification 
of the specific variants that directly influence a trait has proven difficult.  As demonstrated 
throughout the dissertation, to be effective in the identification of risk variants, future studies 
need to increase the power to detect an effect, reduce heterogeneity caused by differences in 
populations or genotypes, minimize the chance of false positives, and increase the amount of 
information provided by genetic polymorphisms by using dense maps and combinations of 
markers as haplotypes. 
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